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General introduction.
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Aspergillus.
In 1729 Aspergillus was first described by priest and biologist Antonio Michelli, 
who named the fungus because of its microscopic resemblance to an 
aspergillum, which is a tool used by priests for sprinkling holy water. Since then, 
over 180 species within its genus were identified based on differences in macro- 
and microscopic morphological features. At present, multilocus sequence-
based phylogenetic analyses of mainly β-tubulin or calmodulin sequences have 
emerged as the primary tool for Aspergillus species identification. Since then, 
numerous new species have been proposed for the most prevalent Aspergillus 
sections including Fumigati, Flavi, Terrei, Nidulanti and Nigri.[1] Aspergillus 
section Fumigati now contains as many as 25 different species, 8 anamorphs 
and 17 teleomorphs, based on sequence-based identification.[2] Aspergillus 
is a saprophytic mould, found worldwide and one of the characteristics of its 
biological life-cycle is the high sporulating capacity in which it ubiquitously 
presents high concentrations of conidia (1-100 conidia m3) in the environment 
(Figure 1). These conidia are continuously inhaled by humans but are seldom 
pathogenic due to an efficient elimination by entrapment in airway mucus and 
ciliary beating and innate immune responses consisting of phagocytic activity and 
antifungal killing by alveolar macrophages.[3] Though, in immunocompromised 
patients and patient with underlying chronic pulmonary illnesses, Aspergillus 
species are capable of establishing a wide variety of diseases.[4] 
Aspergillus disease.
Many authors describe Aspergillus as ‘the multi-artist’ as it is able to cause a 
wide range of diseases (Figure 2).[5-10] Thirty-three Aspergillus species have 
been associated with human disease.[11] The term ‘aspergillosis’ refers to 
illness due to any species of Aspergillus, but A. fumigatus is the most formidable 
Aspergillus causative species in most regions in the world, followed by A. flavus.
[4] However, the illnesses caused by different species of Aspergillus are clinically 
Figure 1. Microscopic detail (100x) 
of Aspergillus on lactophenol cotton 
blue staining, showing conidiophores 
with conidia. With courtesy of H.A.L. 
van der Lee.
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indistinguishable. Besides this, the extent of hyphal invasion in an individual 
patient is generally not due to extrinsic factors, like an increasing concentration of 
airborne Aspergillus conidia, or intrinsic characteristics of the fungus, but depends 
mainly on patient-related risk factors rendering them immunocompromised. 
Persistent neutropenia in patients with malignancies, recipients of hematopoietic 
stem cell or solid organ transplants, functional deficiencies in phagocytic cells 
as seen in patients with primary immunodeficiencies, and patients receiving 
prolonged treatment with corticosteroids display the highest risk for developing 
invasive aspergillosis. Chronic pulmonary aspergillosis (CPA) is a clinical entity 
observed in both patients with chronic obstructive pulmonary disease and 
cystic fibrosis patients. Although, in both patient groups the differentiation 
between colonization and disease is cumbersome and at present it is not clear if 
the presence of Aspergillus species in the CF lung contributes to progressive lung 
disease.[12-14] Allergic bronchopulmonary aspergillosis (ABPA) is observed in 
up to 12% in CF patients and is seen sporadically in patients with asthma.[15] An 
aspergilloma is the development of a fungal mass (fungal ball) in a preexistent 
pulmonary cavity, caused by tuberculosis or other cavitating lung disorders 
(e.g. sarcoidosis). Over the past years, major advances in healthcare resulting in 
an increased number of immunocompromised patients have led to a four-fold 
increase in the incidence of life-threatening Aspergillus infections, with up to 
12% in allograft hematopoietic stem cell transplant recipients.[16,17]
 
Figure 2. Clinical spectrum of Aspergillus diseases: the interaction of Aspergillus with the 
host. Adapted from Kosmidis C, Denning DW. Postgrad Med J 2015;91:403-10.[10]
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(Angio-)invasive aspergillosis:
Airborne conidia of A. fumigatus overcome the primary immune defense 
mechanisms of the lung in the immunocompromised patient, where they 
germinate in the alveoli and produce hyphae invading the lung tissue.[3] 
Besides invasion of lung tissue (70%), dissemination may occur to other organs, 
especially brain, thyroid and kidneys in 9% of patients with Aspergillus disease.
[18] Patients being most at risk of invasive disease are those with prolonged 
and severe neutropenia, glucocorticoid therapy, hematopoietic and solid organ 
transplantation, acute and chronic graft-versus-host disease, advanced AIDS and 
chronic granulomatous disease.[4,16,19-21] Incidence rates vary according to the 
underlying disease of the patient, and range from 0.4% to 14% in patients who 
undergo haematopoietic stem cell transplantation to 0.3% to 6.9% in patients 
with other causes of immunosuppression admitted to the ICU.[22,23] A recent 
French study showed a significant increase of invasive aspergillosis over the last 
few years (2001-2010) of 2.7% in patients with hematological malignancies and 
of 9.8% in patients who underwent haematopoietic stem cell transplantation.
[24]          
 A prompt diagnosis of invasive aspergillosis is crucial, as early antifungal 
therapy corresponds with a better response.[25,26] However, establishing 
a timely diagnosis remains difficult due to non-specific symptomatology, 
late appearance of radiological signs and moreover the low sensitivity of 
microbiologic cultures (positive cultures in 25-50% of patients with invasive 
disease).[27] Furthermore, cultures become often positive when the disease 
is advanced and the fungal burden relatively high. Antigen detection in blood 
and broncho-alveolar lavage (BAL) fluid has become an important diagnostic 
tool in diagnosing invasive disease. Examples of modern diagnostics are 
galactomannan, which is a component of the Aspergillus cell wall, beta-D-
glucan, which is positive in a broad range of fungi, and PCR-amplification of 
fungal DNA.[28-32] However, the best possible option for conclusive diagnosis is 
a positive culture from a normally sterile environment combined with histologic 
confirmation, but this requires invasive procedures, which are commonly not 
tolerated in patients who are extremely ill or have other contraindications such 
as thrombocytopenia. Newer diagnostic tools, like volatile organic compound 
detection in exhaled air, have become available, though their diagnostic value 
still needs to be investigated.[33]      
 Invasive aspergillosis is lethal in 85% of untreated patients, but through 
effective therapy the mortality rate has fallen to below 28.5%.[17,18,24,34,35]
Chronic airway invasive aspergillosis:
Chronic pulmonary aspergillosis (CPA) is a more indolent form of pulmonary 
aspergillosis and occurs in various histological forms, from simple aspergilloma, 
to chronic cavitary pulmonary aspergillosis and to chronic fibrosing pulmonary 
aspergillosis, both with and without aspergilloma’s. Unlike acute (angio-) 
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invasive aspergillosis, CPA occurs in apparently immunocompetent patients. 
In most patients their host defenses are in an impaired state due to conditions 
like diabetes mellitus, a connective tissue disorder, poor nutrition, chronic 
obstructive pulmonary disease, asthma or low dose corticosteroid therapy. 
Aspergilloma are classically observed in patients left with lung cavities after 
pulmonary tuberculosis. It is believed to have an enormous underestimated 
global burden. In 2007 an estimated amount of 372,000 patients developed 
CPA, of which 11,400 in Europe and 145,372 in South-East Asia. The estimated 
prevalence rate ranged from < 1 case per 100,000 in large western European 
countries and the United States of America to 42.9 per 100,000 in both the 
Democratic Republic of the Congo and Nigeria. CPA has a case fatality rate of 
20–33% in the short-term and of 50% over a span of 5 years.[36] 
 Patients with aspergilloma are usually asymptomatic and mortality is 
low when compared to invasive disease, with a case-fatality rate of 29.5%.[18] 
Lethality is caused by severe hemoptysis from an aspergilloma affecting the 
pulmonary vasculature. Medical treatment for aspergilloma is often ineffective, 
whereas surgical resection of the infected lung cavity is the definite therapy.
[37] ABPA or severe asthma associated with fungal sensitization (SAFS) are 
allergic manifestations of Aspergillus colonization which consist of a unique 
Th2-cell mediated immune response and can cause severe bronchial asthma 
exacerbations which may proceed to histologic forms of CPA and end-stage lung 
fibrosis.[38,39] The prevalence of ABPA in asthma patients may be as high as 
13%.[40] 
Last, chronic tracheobronchitis is seen in patients undergoing lung 
transplantation and is due to colonization of the anastomosis. This disease entity 
ranges from relatively mild tracheobronchitis with excess mucus production 
and inflammation to ulcerative tracheobronchitis with ulcers (often around the 
suture line) and extensive pseudomembranous tracheobronchitis.[41]
Treatment of Aspergillus disease.
Currently, there are 3 classes of antifungal drugs with activity to Aspergillus 
species (Table 1), and might be used for prevention or treatment of invasive 
aspergillosis.
Polyenes 
Polyene agents bind to ergosterol of the fungal cell wall, alter its permeability 
and cause oxidative stress and thereby cause rapid cell death. Historically, 
amphotericin B has been the major antifungal drug used for treating aspergillus 
diseases, but currently has been replaced by other antifungals due to the 
frequent encounter of nephrotoxicity and other lipid-based formulations that 
became available that exhibit an improved tolerability.[42-49]
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Azoles
The mold-active azole compounds are considered to be the backbone of 
treatment of Aspergillus diseases. In the two past decades four different azole 
compounds became available, being respectively itraconazole, voriconazole, 
posaconazole and isavuconazole. Triazoles bind with their nitrogen group to 
the heme group located in the center of the Cyp51A-protein and thereby block 
sterol 14-alfa-demethylase, which is an enzyme in the ergosterol pathway 
of the fungus. Besides this, the accumulation of sterol intermediates will 
cause toxic stress.[34,35,37,56-66]       
 
Echinocandins
Echinocandins inhibit (1,3)-β-d-glucan synthesis and thereby inhibit hyphal-
growth. It causes aberrant growth of hyphae at the apical tips, but absolute 
killing does not occur. Caspofungin is the longest serving echinocandin with 
micafungin and anidulafungin completing the arsenal of echinocandins in the 
recent years. They are very well tolerated and have few drug interactions, though 
currently cannot be recommended for primary therapy of invasive aspergillosis 
as phase II studies indicated a lower efficacy than can be expected with azole 
drugs.[67-70] 
In-vitro susceptibility testing of Aspergillus species.
For determination or prediction of the susceptibility profile of the causative 
agent in Aspergillus diseases a variety of methods have been proposed in the 
last two decades. 
Microbroth dilution methods
There are currently two reference methods for in vitro susceptibility testing of 
Aspergillus species: the method of the Clinical Laboratory Standards Institute 
(CLSI) and of the European Committee for Antimicrobial Susceptibility Testing 
(EUCAST). The methods both have a microbroth dilution format using RPMI-1640 
medium. The minimum inhibition concentration (MIC) is read visually after 48 
hours of incubation. The EUCAST-method has determined clinical breakpoints 
for several Aspergillus species-antifungal drug combinations, including those for 
A. fumigatus and itraconazole, voriconazole and posaconazole.[71-74] 
Agar dilution method and e-test
Disk-based susceptibility testing is convenient, simple and economical. The 
optimal testing conditions for Aspergillus disk diffusion testing are known. Agar-
based methods hold promise as simple and reliable methods for determining 
susceptibilities of filamentous fungi. The commercial e-test method is suitable 
for Aspergilli and is a reliable and reproducible method. The results correlate 
well with the CLSI methodology, though MIC reading of echinocandins against 
Aspergillus might be troublesome because of heavy growth within a discrete 
ellipse.[74]
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rm
ac
ok
in
et
ic
s i
n 
ad
ul
ts
. B
ec
au
se
 o
f v
ar
ia
bl
e 
po
pu
la
tio
n 
ph
ar
m
ac
ok
in
et
ic
s a
nd
 d
os
e–
re
sp
on
se
 
re
la
tio
ns
hi
ps
, t
he
 n
ar
ro
w
 th
er
ap
eu
tic
 
w
in
do
w
, a
nd
 a
 c
lin
ic
al
ly
 d
ef
in
ed
 
th
er
ap
eu
tic
 ra
ng
e 
fo
r c
lin
ic
al
 re
sp
on
se
, 
th
er
ap
eu
tic
 d
ru
g 
m
on
ito
rin
g 
is
 e
ss
en
tia
l, 
es
pe
ci
al
ly
 in
 c
hi
ld
re
n,
 in
 w
ho
m
 c
le
ar
an
ce
 
is
 li
ne
ar
 a
nd
 m
or
e 
ra
pi
d.
Vi
su
al
 d
is
tu
rb
an
ce
s,
 sk
in
 ra
sh
es
, 
ha
llu
ci
na
tio
ns
, a
nd
 h
ep
at
ot
ox
ic
ity
 a
re
 
re
po
rt
ed
.  
Lo
ng
-te
rm
 u
se
 is
 a
ss
oc
ia
te
d 
w
ith
 
un
ex
pe
ct
ed
 si
de
 e
ffe
ct
s t
ha
t i
nc
lu
de
 
al
op
ec
ia
, p
er
io
st
iti
s f
ro
m
 fl
uo
rid
e 
ex
ce
ss
, 
an
d 
de
ve
lo
pm
en
t o
f s
ki
n 
ca
nc
er
s.
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Po
sa
co
na
zo
le
Li
ce
ns
ed
 fo
r a
nt
ifu
ng
al
 p
ro
ph
yl
ax
is
 in
 
he
m
at
ol
og
ic
al
 h
ig
h-
ris
k 
pa
tie
nt
s a
nd
 fo
r 
sa
lv
ag
e 
th
er
ap
y 
of
 in
va
si
ve
 a
sp
er
gi
llo
si
s.
 
Po
sa
co
na
zo
le
 is
 e
ffe
ct
iv
e 
as
 p
ro
ph
yl
ax
is
 in
 
pa
tie
nt
s w
ith
 m
ye
lo
dy
sp
la
st
ic
 sy
nd
ro
m
e 
or
 
ac
ut
e 
m
ye
lo
ge
no
us
 le
uk
em
ia
 a
nd
 p
at
ie
nt
s 
w
ith
 se
ve
re
 G
VH
D.
 T
he
re
 is
 n
o 
ev
id
en
ce
 fo
r 
us
in
g 
po
sa
co
na
zo
le
 a
s p
rim
ar
y 
th
er
ap
y,
 
al
th
ou
gh
 st
ud
ie
s a
re
 o
ng
oi
ng
 w
ith
 th
e 
in
tr
av
en
ou
s f
or
m
ul
at
io
n 
of
 th
e 
dr
ug
.
Av
ai
la
bl
e 
in
 o
ra
l a
nd
 in
tr
av
en
ou
s f
or
m
s.
 
Th
e 
ne
w
ly
 a
pp
ro
ve
d 
de
la
ye
d-
re
le
as
e 
ta
bl
et
 a
nd
 in
tr
av
en
ou
s f
or
m
ul
at
io
ns
 
di
sp
la
y 
m
or
e 
co
ns
is
te
nt
 b
io
av
ai
la
bi
lit
y 
in
 th
e 
pr
es
en
ce
 o
f c
on
co
m
ita
nt
 d
is
ea
se
 
st
at
es
, m
ed
ic
at
io
ns
, a
nd
 d
ie
ta
ry
 
co
ns
id
er
at
io
ns
 th
at
 c
la
ss
ic
al
ly
 a
lte
r d
ru
g 
co
nc
en
tr
at
io
ns
 o
f t
he
 o
ra
l s
us
pe
ns
io
n.
 
Th
er
ap
eu
tic
 d
ru
g 
m
on
ito
rin
g 
se
em
ed
 
to
 b
e 
a 
he
lp
fu
l t
oo
l t
o 
id
en
tif
y 
lo
w
 
co
nc
en
tr
at
io
ns
 a
nd
 to
 o
pt
im
iz
e 
po
sa
co
na
zo
le
 tr
ea
tm
en
t.
N
o 
se
rio
us
 si
de
 e
ffe
ct
s a
re
 re
po
rt
ed
, b
ut
 
he
ad
ac
he
, f
ev
er
, n
au
se
a,
 v
om
iti
ng
, a
nd
 
di
ar
rh
ea
 c
an
 o
cc
ur
. R
ar
el
y,
 h
ep
at
ot
ox
ic
ity
 
an
d 
Q
T 
in
te
rv
al
 p
ro
lo
ng
at
io
n 
ha
ve
 b
ee
n 
re
po
rt
ed
.
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Is
av
uc
on
az
ol
e
In
 v
itr
o 
ac
tiv
ity
 a
ga
in
st
 m
os
t A
sp
er
gi
llu
s 
is
ol
at
es
 a
nd
 h
as
 a
ls
o 
be
en
 sh
ow
n 
to
 b
e 
eff
ec
tiv
e 
in
 a
ni
m
al
 m
od
el
s o
f d
is
se
m
in
at
ed
 
as
pe
rg
ill
os
is
, t
ho
ug
h 
it 
is
 c
ur
re
nt
ly
 in
 P
ha
se
 
III
 c
lin
ic
al
 d
ev
el
op
m
en
t f
or
 tr
ea
tm
en
t o
f 
as
pe
rg
ill
os
is
.
Av
ai
la
bl
e 
in
 o
ra
l a
nd
 in
tr
av
en
ou
s f
or
m
s.
 
W
he
n 
co
m
pa
re
d 
to
 v
or
ic
on
az
ol
e 
it 
ha
s 
sh
ow
n 
lo
w
 to
 m
od
er
at
e 
in
te
rs
ub
je
ct
 
va
ria
bi
lit
y 
in
 se
ru
m
 le
ve
ls
.
Si
de
 e
ffe
ct
s o
f h
ea
da
ch
e,
 rh
in
iti
s,
 
na
so
ph
ar
yn
gi
tis
, m
od
er
at
e 
di
ar
rh
ea
, 
na
us
ea
, a
nd
 m
ild
 u
pp
er
 a
bd
om
in
al
 p
ai
n 
ha
ve
 b
ee
n 
se
en
 in
 h
ea
lth
y 
vo
lu
nt
ee
r 
st
ud
ie
s.
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Ec
hi
no
ca
nd
in
s
Ca
sp
of
un
gi
n
Th
e 
tr
ea
tm
en
t o
f i
nv
as
iv
e 
as
pe
rg
ill
os
is
 w
ith
 
ca
sp
of
un
gi
n,
 m
ic
af
un
gi
n,
 o
r a
ni
du
la
fu
ng
in
 
as
 p
rim
ar
y 
th
er
ap
y 
ha
s n
ot
 b
ee
n 
ex
am
in
ed
 
in
 a
 ra
nd
om
iz
ed
 c
on
tr
ol
le
d 
m
an
ne
r. 
In
 
vi
tr
o 
th
e 
ec
hi
no
ca
nd
in
s h
av
e 
si
m
ila
r o
r 
be
tt
er
 fu
ng
is
ta
tic
 a
ct
iv
ity
 th
an
 th
os
e 
of
 
am
ph
ot
er
ic
in
 B
 a
nd
 th
e 
tr
ia
zo
le
s.
 T
he
 
th
er
ap
eu
tic
 e
ffi
ca
cy
 o
f c
as
po
fu
ng
in
 is
 
su
pe
rio
r t
o 
am
ph
ot
er
ic
in
 B
 a
nd
 h
as
 
de
m
on
st
ra
te
d 
eff
ic
ac
y 
as
 e
m
pi
ric
 tr
ea
tm
en
t 
of
 fe
br
ile
 n
eu
tr
op
en
ia
 a
nd
 sa
lv
ag
e 
th
er
ap
y 
fo
r t
he
 tr
ea
tm
en
t o
f i
nv
as
iv
e 
as
pe
rg
ill
os
is
. 
Ca
sp
of
un
gi
n 
is
 a
pp
ro
ve
d 
by
 th
e 
FD
A 
as
 
sa
lv
ag
e 
th
er
ap
y 
fo
r i
nv
as
iv
e 
as
pe
rg
ill
os
is
. 
N
on
e 
of
 th
e 
ec
hi
no
ca
nd
in
s i
s a
pp
ro
ve
d 
fo
r 
th
e 
us
e 
in
 p
ed
ia
tr
ic
 p
at
ie
nt
s.
 
M
in
im
al
 e
ffe
ct
iv
e 
co
nc
en
tr
at
io
ns
 o
f 
m
ic
af
un
gi
n 
an
d 
an
id
ul
fu
ng
in
 a
re
 2
- t
o 
10
-fo
ld
 
lo
w
er
 th
an
 th
os
e 
fo
r c
as
po
fu
ng
in
.  
Sy
ne
rg
is
tic
/a
dd
iti
ve
 in
 v
itr
o 
eff
ec
ts
 (i
n 
pr
es
en
ce
 o
f s
er
um
) o
f e
ch
in
oc
an
di
ns
 w
he
n 
co
m
bi
ne
d 
w
ith
 a
 p
ol
ye
ne
 o
r a
zo
le
 h
av
e 
be
en
 
ob
se
rv
ed
, a
nd
 it
 a
pp
ea
rs
 th
at
 m
or
ta
lit
y 
is
 
re
du
ce
d 
w
ith
 c
om
bi
na
tio
n 
th
er
ap
y 
co
m
pa
re
d 
w
ith
 m
on
ot
he
ra
py
.
Av
ai
la
bl
e 
in
 in
tr
av
en
ou
s f
or
m
. D
is
tr
ib
ut
e 
w
el
l i
nt
o 
tis
su
es
, b
ut
 p
oo
rly
 in
to
 th
e 
ce
nt
ra
l n
er
vo
us
 sy
st
em
 a
nd
 e
ye
.
Ph
le
bi
tis
, h
ea
da
ch
e,
 ra
sh
, p
ru
rit
is
, 
hy
po
ka
le
m
ia
 a
nd
 e
le
va
te
d 
liv
er
 
en
zy
m
es
 a
re
 re
po
rt
ed
. A
 h
ig
he
r r
at
e 
of
 
ad
ve
rs
e 
re
ac
tio
ns
 h
as
 b
ee
n 
re
po
rt
ed
 fo
r 
ca
sp
of
un
gi
n 
co
m
pa
re
d 
w
ith
 m
ic
af
un
gi
n 
an
d 
an
id
ul
af
un
gi
n,
 th
ou
gh
 d
at
a 
w
ith
 
an
id
ul
af
un
gi
n 
ar
e 
lim
ite
d.
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M
ic
af
un
gi
n
An
id
ul
af
un
gi
n
Ta
bl
e 
1.
 A
nt
ifu
ng
al
 a
ge
nt
s w
ith
 a
ct
iv
ity
 a
ga
in
st
 A
sp
er
gi
llu
s s
pe
ci
es
.
An
tif
un
ga
l 
gr
ou
p
Dr
ug
Eff
ic
ac
y 
of
 tr
ea
tm
en
t
Ph
ar
m
ac
ok
in
et
ic
s
To
le
ra
bi
lit
y
Re
fe
re
nc
e
Po
ly
en
es
N
eb
ul
iz
ed
  
lip
os
om
al
 
am
ph
ot
er
ic
in
 B
Lo
ng
-te
rm
 a
dm
in
is
tr
at
io
n 
of
 p
ro
ph
yl
ax
is
 c
an
 
be
 u
se
d 
fo
r d
ec
ol
on
iz
at
io
n 
an
d 
pr
ev
en
tin
g 
IP
A 
in
 lu
ng
 tr
an
sp
la
nt
 re
ci
pi
en
ts
. I
t w
as
 a
ls
o 
ev
al
ua
te
d 
as
 a
n 
an
tif
un
ga
l p
ro
ph
yl
ax
is
 in
 
pa
tie
nt
s w
ith
 h
em
at
ol
og
ic
 d
is
ea
se
s,
 b
ut
 
ne
ed
s f
ur
th
er
 in
ve
st
ig
at
io
n.
Aft
er
 n
eb
ul
iz
at
io
n 
co
nc
en
tr
at
io
ns
 
re
m
ai
n 
hi
gh
 fo
r 1
4 
da
ys
, a
t a
de
qu
at
e 
co
nc
en
tr
at
io
ns
 fo
r p
ro
ph
yl
ax
is
 o
f I
PA
. 
N
o 
si
gn
ifi
ca
nt
 sy
st
em
ic
 a
bs
or
pt
io
n 
w
as
 
de
te
ct
ed
 a
nd
 n
o 
eff
ec
t w
as
 o
bs
er
ve
d 
on
 
re
sp
ira
to
ry
 fu
nc
tio
n.
Br
on
ch
os
pa
sm
 a
nd
 n
au
se
a 
ar
e 
re
po
rt
ed
 
in
 a
 lo
w
 fr
eq
ue
nc
y.
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Am
ph
ot
er
ic
in
 B
 
de
ox
yc
ho
la
te
(c
on
ve
nt
io
na
l 
am
ph
ot
er
ic
in
 B
)
Am
ph
ot
er
ic
in
 B
 is
 a
pp
ro
ve
d 
to
 tr
ea
t 
IP
A.
 H
ow
ev
er
, t
he
 u
se
 o
f c
on
ve
nt
io
na
l 
am
ph
ot
er
ic
in
 B
 is
 li
m
ite
d 
by
 si
gn
ifi
ca
nt
 d
os
e-
de
pe
nd
en
t t
ox
ic
ity
.
Av
ai
la
bl
e 
in
 in
tr
av
en
ou
s f
or
m
. S
ho
w
s 
no
nl
in
ea
r p
ha
rm
ac
ok
in
et
ic
s,
 w
ith
 h
ig
he
r 
th
an
 d
os
e-
pr
op
or
tio
na
l i
nc
re
as
es
.
Fe
ve
r, 
ch
ill
s,
 h
ea
da
ch
e,
 n
au
se
a 
an
d 
vo
m
iti
ng
, r
ig
or
s,
 re
sp
ira
to
ry
 c
om
pr
om
is
e,
 
el
ec
tr
ol
yt
e 
ab
no
rm
al
iti
es
 (h
yp
ok
al
em
ia
, 
hy
po
m
ag
ne
se
m
ia
, h
yp
er
na
tr
em
ia
, a
nd
 
m
et
ab
ol
ic
 a
ci
do
si
s)
 a
re
 re
po
rt
ed
, t
ho
ug
h 
ne
ph
ro
to
xi
ci
ty
 o
cc
ur
s i
n 
30
%
 o
f p
at
ie
nt
s.
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Li
po
so
m
al
 
am
ph
ot
er
ic
in
 B
In
fe
rio
r t
o 
vo
ric
on
az
ol
e 
as
 fi
rs
t l
in
e 
tr
ea
tm
en
t 
of
 IP
A,
 th
ou
gh
 c
on
si
de
re
d 
a 
fir
st
 li
ne
 o
pt
io
n 
fo
r e
m
pi
ric
al
 th
er
ap
y 
in
 n
eu
tr
op
en
ic
 p
at
ie
nt
s 
w
ith
 fe
ve
r a
t h
ig
h 
ris
k 
of
 IP
A.
  
Th
e 
re
du
ce
d 
to
xi
ci
ty
 o
f t
he
 li
pi
d 
fo
rm
ul
at
io
ns
 
of
 a
m
ph
ot
er
ic
in
 c
on
tr
ib
ut
ed
 to
 th
e 
ov
er
al
l 
im
pr
ov
ed
 o
ut
co
m
e 
in
 c
om
pa
ra
tiv
e 
st
ud
ie
s,
 
al
lo
w
in
g 
fo
r t
he
 u
se
 o
f h
ig
he
r d
os
es
 w
ith
 
be
tt
er
 fu
ng
al
 k
ill
in
g 
an
d 
le
ss
 si
de
 e
ffe
ct
s,
 
th
ou
gh
 th
e 
lip
id
-a
ss
oc
ia
te
d 
pr
ep
ar
at
io
ns
 d
id
 
no
t a
pp
ea
r t
o 
pr
ov
id
e 
a 
su
rv
iv
al
 b
en
ef
it 
ov
er
 
co
nv
en
tio
na
l a
m
ph
ot
er
ic
in
 B
 d
eo
xy
ch
ol
at
e.
Sa
m
e 
as
 a
m
ph
ot
er
ic
in
 B
 d
eo
xy
ch
ol
at
e,
 
bu
t b
ec
au
se
 o
f i
ts
 sm
al
l s
iz
e 
an
d 
ne
ga
tiv
e 
ch
ar
ge
, i
t a
vo
id
s s
ub
st
an
tia
l r
ec
og
ni
tio
n 
an
d 
up
ta
ke
 b
y 
th
e 
m
on
on
uc
le
ar
 
ph
ag
oc
yt
e 
sy
st
em
. T
he
re
fo
re
, a
 si
ng
le
 
do
se
 o
f r
es
ul
ts
 in
 a
 m
uc
h 
hi
gh
er
 p
ea
k 
pl
as
m
a 
le
ve
l  
th
an
 c
on
ve
nt
io
na
l 
am
ph
ot
er
ic
in
 B
 d
eo
xy
ch
ol
at
e 
an
d 
a 
m
uc
h 
la
rg
er
 a
re
a 
un
de
r t
he
 c
on
ce
nt
ra
tio
n-
tim
e 
cu
rv
e.
 
Sa
m
e 
as
 a
m
ph
ot
er
ic
in
 B
 d
eo
xy
ch
ol
at
e,
 
th
ou
gh
 si
gn
ifi
ca
nt
ly
 le
ss
 fr
eq
ue
nt
 w
he
n 
gi
ve
n 
at
 n
or
m
al
 d
os
ag
es
.
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Az
ol
es
Itr
ac
on
az
ol
e
Pr
ov
en
 to
 b
e 
eff
ec
tiv
e 
as
 p
ro
ph
yl
ax
is
 in
 C
GD
 
pa
tie
nt
s a
nd
 in
 C
F 
an
d 
as
th
m
at
ic
 p
at
ie
nt
s 
w
ith
 A
BP
A.
 F
ur
th
er
m
or
e 
it 
ca
n 
be
 u
se
d 
as
 
pr
op
hy
la
xi
s f
or
 in
va
si
ve
 A
sp
er
gi
llu
s i
nf
ec
tio
ns
 
in
 n
eu
tr
op
en
ic
 p
at
ie
nt
s.
Av
ai
la
bl
e 
in
 o
ra
l a
nd
 in
tr
av
en
ou
s f
or
m
s.
 
Th
e 
bi
oa
va
ila
bi
lit
y 
is
 h
ig
hl
y 
va
ria
bl
e.
 It
 h
as
 
po
or
 p
en
et
ra
tio
n 
in
to
 th
e 
ce
nt
ra
l n
er
vo
us
 
sy
st
em
. T
he
ra
pe
ut
ic
 d
ru
g 
m
on
ito
rin
g 
an
d 
m
ea
su
re
m
en
t o
f s
er
um
 c
on
ce
nt
ra
tio
ns
 a
re
 
hi
gh
ly
 re
co
m
m
en
de
d.
Do
se
-r
el
at
ed
 n
au
se
a 
an
d 
vo
m
iti
ng
, 
lik
el
y 
du
e 
to
 th
e 
cy
cl
od
ex
tr
in
 u
se
d 
to
 
so
lu
bl
iz
e 
th
e 
m
ed
ic
at
io
n 
ar
e 
re
po
rt
ed
. 
H
ig
h 
do
se
s o
f t
he
 m
ed
ic
at
io
n 
ca
n 
ha
ve
 
an
 a
ld
os
te
ro
ne
-li
ke
 e
ffe
ct
, m
an
ife
st
ed
 b
y 
hy
po
ka
le
m
ia
, e
de
m
a,
 a
nd
 h
yp
er
te
ns
io
n.
 
Ca
se
s o
f c
on
ge
st
iv
e 
he
ar
t f
ai
lu
re
 h
av
e 
be
en
 re
po
rt
ed
, a
nd
 th
er
ef
or
e 
ca
ut
io
n 
sh
ou
ld
 b
e 
us
ed
 in
 p
at
ie
nt
s w
ith
 
ve
nt
ric
ul
ar
 d
ys
fu
nc
tio
n.
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Vo
ric
on
az
ol
e
Su
pe
rio
r t
o 
(c
on
ve
nt
io
na
l) 
am
ph
ot
er
ic
in
 B
, 
sh
ow
in
g 
a 
si
gn
ifi
ca
nt
 im
pr
ov
ed
 su
rv
iv
al
 (7
1%
 
ve
rs
us
 5
8%
), 
an
d 
is
 a
pp
ro
ve
d 
fo
r f
irs
t-l
in
e 
th
er
ap
y 
of
 IP
A.
 In
 a
 si
ng
le
-c
en
te
r s
tu
dy
 w
ith
 
40
5 
he
m
at
op
oe
tic
 st
em
 c
el
l t
ra
ns
pl
an
ta
tio
n 
pa
tie
nt
s w
ith
 p
ro
ba
bl
e 
or
 p
ro
ve
n 
in
va
si
ve
 
as
pe
rg
ill
os
is
 th
e 
w
id
es
pr
ea
d 
us
e 
of
 
vo
ric
on
az
ol
e 
si
nc
e 
20
02
 w
as
 a
ss
oc
ia
te
d 
w
ith
 re
du
ce
d 
ris
k 
of
 d
ea
th
 in
 th
e 
un
iv
ar
ia
te
 
an
al
ys
es
.
Av
ai
la
bl
e 
in
 o
ra
l a
nd
 in
tr
av
en
ou
s f
or
m
s.
 
Th
e 
or
al
 fo
rm
 h
as
 a
 b
io
av
ai
la
bi
lit
y 
of
 
gr
ea
te
r t
ha
n 
90
%
. P
en
et
ra
te
s w
el
l i
nt
o 
th
e 
ce
nt
ra
l n
er
vo
us
 sy
st
em
. 
Sh
ow
s n
on
lin
ea
r p
ha
rm
ac
ok
in
et
ic
s i
n 
ad
ul
ts
. B
ec
au
se
 o
f v
ar
ia
bl
e 
po
pu
la
tio
n 
ph
ar
m
ac
ok
in
et
ic
s a
nd
 d
os
e–
re
sp
on
se
 
re
la
tio
ns
hi
ps
, t
he
 n
ar
ro
w
 th
er
ap
eu
tic
 
w
in
do
w
, a
nd
 a
 c
lin
ic
al
ly
 d
ef
in
ed
 
th
er
ap
eu
tic
 ra
ng
e 
fo
r c
lin
ic
al
 re
sp
on
se
, 
th
er
ap
eu
tic
 d
ru
g 
m
on
ito
rin
g 
is
 e
ss
en
tia
l, 
es
pe
ci
al
ly
 in
 c
hi
ld
re
n,
 in
 w
ho
m
 c
le
ar
an
ce
 
is
 li
ne
ar
 a
nd
 m
or
e 
ra
pi
d.
Vi
su
al
 d
is
tu
rb
an
ce
s,
 sk
in
 ra
sh
es
, 
ha
llu
ci
na
tio
ns
, a
nd
 h
ep
at
ot
ox
ic
ity
 a
re
 
re
po
rt
ed
.  
Lo
ng
-te
rm
 u
se
 is
 a
ss
oc
ia
te
d 
w
ith
 
un
ex
pe
ct
ed
 si
de
 e
ffe
ct
s t
ha
t i
nc
lu
de
 
al
op
ec
ia
, p
er
io
st
iti
s f
ro
m
 fl
uo
rid
e 
ex
ce
ss
, 
an
d 
de
ve
lo
pm
en
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Molecular mechanisms and direct detection of resistance mechanisms. 
However, variable MIC profiles (for each isolate and for each antifungal drug) 
make it possible to miss resistance if screening is performed using a single 
antifungal.[75] A real-time polymerase chain reaction (PCR) assay to detect 
Aspergillus species in bronchoalveolar lavage (BAL) and sputum specimens 
was used in 2011. In sputum in 15 of 19 (78.9%) and 30 of 42 (71.4%) patients 
with ABPA and CPA Aspergillus was found. The CYP51A gene, known to be 
involved in resistance-development, was further amplified to detect key single-
nucleotide polymorphisms (SNPs) and contained SNPs associated with triazole 
resistance in 55.1% of samples.[76] Further novel PCR assays to detect azole 
resistance-mediating mutations of Aspergillus fumigatus from clinical samples 
in neutropenic patients can be used to detect azole resistance and to optimize 
antifungal therapy in patients with aspergillosis.[77] 
 
Failure to treatment of Aspergillus disease.
Resistance to azole compounds can be divided into two groups, with some 
Aspergillus (non-fumigatus) species long-time known to be intrinsically resistant 
and the other group, containing Aspergillus fumigatus sensu stricto isolates, 
which acquired a mechanism of resistance to azole drugs being recognized in 
recent years.
Intrinsic resistance in Aspergillus isolates.
Until recently, Aspergillus species identification was primarily based on 
macroscopic and microscopic morphology and sufficient to guide antifungal 
therapy. Recent taxonomic changes have led to the classification of cryptic 
Aspergillus species that exhibit in vitro susceptibility profiles that differ 
significantly from that of Aspergillus fumigatus sensu stricto.[78-80] For non-
fumigatus Aspergillus isolates interpretative breakpoints are not available and 
it is not possible to classify specific species or isolates based on the MIC. The 
in vitro activity of antifungal agents of non-fumigatus Aspergillus isolates is 
often compared with A. fumigatus. However, the experience with MIC-testing of 
non-fumigatus Aspergillus isolates is limited and the growth characteristics or 
production of foliates may have impact on the MIC results or its reproducibility. 
Nevertheless, the recent taxonomic changes require us to reestablish the MIC 
distributions of the species complexes and their newly defined Aspergillus 
species. In addition to investigating the wild type MIC distributions, the role of 
the new sibling species in invasive fungal infections needs to be established. 
Acquired resistance in A. fumigatus.
Resistance development in bacteria and viruses is a well-known phenomenon, 
but was unknown for fungal pathogens until 1994 when the first observations 
of fluconazole resistance in Candida albicans were reported.[81] In the late 
1990s first reports emerged of A. fumigatus sensu stricto having acquired a 
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resistant phenotype.[82] Azole resistance has been found mainly in A. fumigatus 
following chronic azole therapy, and was thereby supposed to be acquired.[83-
86] Patients receiving chronic azole therapy, mostly itraconazole, are those with 
aspergilloma in the lung or those with CPA or ABPA were vulnerable to resistance 
development.[84,85] In these patients resistance is most commonly observed 
in A. fumigatus and the isolates may be resistant to only itraconazole or exhibit 
a multi-azole or pan-azole resistant phenotype.[87] The phenotype depends 
on the underlying resistance mechanism, which commonly involves point-
mutations in the Cyp51A-gene, the target for antifungal azoles.[71,84,85,88-94] 
This route of acquired resistance in A. fumigatus has long been perceived as a 
manageable problem as resistance development during azole therapy has been 
reported with only a very low frequency.[95-97] 
 In the Netherlands a second route of resistance development was 
suggested where clinical A. fumigatus isolates may have become resistant 
through environmental exposure to 14α-demethylase inhibitors (DMIs).[88,98-
100] The first resistance mechanism that is believed to be of environmental 
origin consists of a substitution of leucine for histidine at codon 98 in the 
cyp51A gene in combination with a 34 base pair tandem repeat in the gene 
promoter (TR34/L98H).[98] The corresponding phenotype showed resistance to 
itraconazole, and intermediate susceptibility or resistance to voriconazole and/
or posaconazole.[71,88] DMIs inhibit fungal Cyp51A and are abundantly used for 
crop protection and material preservation. Although A. fumigatus is not a target-
organism for azole-fungicides, many of these were found to exhibit in vitro 
activity against A. fumigatus. Five DMIs, all from the triazole class, showed in vitro 
activity against wild type A. fumigatus but not against isolates harbouring the 
TR34/L98H resistance mechanism. Moreover, these five fungicides were shown to 
have a molecule structure that was highly similar to that of the clinically licensed 
triazoles, and models of the CYP51A-protein indicated that the binding to heme 
was most hindered in these fungicides when TR34/L98H was present.[99] Based 
on these observations it was hypothesized that A. fumigatus acquires resistance 
mechanisms through exposure to azole fungicides in the environment. Patients 
may inhale azole-resistant spores and subsequently develop azole-resistant 
aspergillosis. Due to the molecule similarity between certain azole fungicides 
and the medical triazoles, the activity of the latter is lost and patient fails to azole 
therapy.
Epidemiology and surveillance of resistance.
In 2009 and 2010 we described a case series of acute invasive aspergillosis caused 
by A. fumigatus resistant to medical triazoles in four patients (Table 2).[8,9] 
Three were diagnosed with CNS aspergillosis and this was the first time azole 
resistant CNS aspergillosis was reported. For the cultured isolates, the MICs of 
both itraconazole and voriconazole were above the concentrations achievable 
in plasma and cerebrospinal fluid, thereby precluding the use of these agents. 
All patients with CNS aspergillosis described in these papers died and, despite 
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Case Sex/ 
age
Specimen MIC
(mg/l)
Mutation(s) Underlying 
disease
Aspergillus 
disease
Previous 
treatment
Outcome Reference
ITZ VCZ POS
1. M/31 Lung 
biopsy
>16 8 0.5 TR34/L98H CGD, COPD IPA ITZ Survived 8
2. F/11  Lung 
biopsy
>16 16 2 TR34/L98H Precursor
B cell 
lymphoblastic 
lymphoma
IPA and CNS 
aspergillosis
None Died 9
3. F/42 Brain 
biopsy
>16 8 0.5 TR34/L98H HIV, COPD CNS 
aspergillosis
None Died 9
4. M/64 Brain 
biopsy
>16 16 0.5 TR34/L98H Colon 
carcinoma 
with liver 
metastases
CNS 
aspergillosis
None Died 9
the generally dismal outcome of CNS aspergillosis, azole resistance precluded 
prompt adequate antifungal therapy. Furthermore, all patients harbored the 
same TR34/L98H resistance mechanism and in none of the patients’ apparent 
risk factors for azole resistance existed: 3 of the 4 patients were not exposed 
previously to mold-active antifungal azoles. This underlines our hypothesis that 
resistance might have developed through fungal adaptation to exposure to azole 
fungicides in the environment.
 Our case-reports showed that azole resistance further complicates the 
management of invasive aspergillosis and should be considered as a cause of 
treatment failure. Investigation of the fungus culture collection of the Radboud 
University Medical Center indicated that azole resistance had emerged in 2000, 
as in over 650 isolates collected between 1994 and 2000 azole resistance was 
not found. However, since the first azole-resistant isolate was found in 2000, 
each year patients with azole-resistant isolates were found with an increasing 
frequency over time. Over 90% of azole-resistant A. fumigatus isolates harbored 
the TR34/L98H resistance mechanism, indicating that the environmental route 
of resistance selection was dominant compared with the patient route. The study 
also indicated that azole resistance was not a local problem as azole resistance 
was found in A. fumigatus isolates sent by other Dutch Centers to Nijmegen 
for in vitro susceptibility testing.[88] As these isolates were not collected 
systematically, there was a clear need to determine the epidemiology of azole 
resistance in patients at risk for Aspergillus diseases and to investigate if patient 
risk factors could be identified. 
Table 2. Clinical characteristics in four patients with acquired azole resistant 
Aspergillus fumigatus disease.      
 
M; male, F; female, ITZ; itraconazole, VCC; voriconazole, POS; posaconazole, CGD; 
chronic granulomatous disease, COPD; chronic obstructive pulmonary disease, HIV; 
human immunodeficiency virus, IPA; invasive pulmonary aspergillosis, CNS; central 
nervous system.
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Until recently in vitro susceptibility testing was not performed routinely 
in many clinical microbiology laboratories, but due to new taxonomic insights 
in Aspergillus classification associated with the recognition of variability in 
susceptibility profiles, and the emergence of acquired resistance the necessity 
to determine susceptibility profiles of clinical isolates will increase.
Objective of this thesis.
The aim of this thesis is to investigate the frequency of azole resistance through 
surveillance of clinical A. fumigatus isolates. In addition to the epidemiology of 
azole resistance and distribution and trends in resistance mechanisms we also 
aimed to identify risk factors associated with azole-resistant Aspergillus disease. 
In chapter 2 the characteristics of azole resistance selection through patient 
therapy was reviewed following a case of a patient who’s isolates changed from 
a wild type phenotype to an azole-resistant phenotype during azole therapy. 
In chapter 3 the results of an epidemiological survey are presented. Through 
screening of clinical A. fumigatus isolates the frequency of azole resistance, 
underlying resistance mechanisms and clinical implications was analysed. 
In this study the TR34/L98H resistance mechanism was found to dominate in 
clinical azole-resistant A. fumigatus isolates. However, in December 2009 a new 
resistance mechanism was found, TR46/Y121F/T289A, associated with high-level 
voriconazole resistance. The migration of this resistance mechanism across 
Dutch hospitals and the recovery from the environment is described in chapter 
4. Finally, a large international surveillance study was performed in order 
to determine the presence and frequency of azole resistance in 19 countries 
(chapter 5). In the last chapter (chapter 6) all the results are discussed in the 
view of our current knowledge and future prospects.
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Drawing made by a 14-year old boy who was suffering from T-cell lymphoma and 
invasive aspergillosis, with pulmonary and cerebral lesions.
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Abstract
Nine consecutive isogenic Aspergillus fumigatus isolates cultured from a patient 
with aspergilloma were investigated for azole resistance. The first cultured 
isolate showed a wild type phenotype, but four azole-resistant phenotypes were 
observed in the subsequent eight isolates. Four mutations were found in the 
cyp51A-gene of these isolates, leading to the substitutions A9T, G54E, P216L, and 
F219I. Only G54 substitutions were previously proved to be associated with azole 
resistance. Using a Cyp51A homology model and recombination experiments in 
which the mutations were introduced into a susceptible isolate, we show that 
the substitutions at codons P216 and F219 were both associated with resistance 
to itraconazole and posaconazole. A9T was also present in the wild type 
isolate and thus considered a Cyp51A-polymorphism. Isolates harboring F219I 
evolved further into a pan-azole-resistant phenotype, indicating an additional 
acquisition of a non-Cyp51A-mediated resistance mechanism. Review of the 
literature showed that in patients who develop azole resistance during therapy, 
multiple resistance mechanisms commonly emerge. Furthermore, the median 
time between the last cultured wild-type isolate and the first azole-resistant 
isolate was 4 months (range 3 weeks to 23 months) indicating a rapid induction 
of resistance.
Introduction
Aspergillus fumigatus is able to cause a wide range of diseases, including allergic 
syndromes, aspergilloma, and invasive aspergillosis. Azoles play an important 
role in the management of Aspergillus diseases, but chronic treatment may cause 
the development of resistance, especially in patients with cavitary lesions, such 
as aspergilloma.[5,14,15] Infection with azole-resistant A. fumigatus is associated 
with a higher probability of treatment failure than infection due to isolates with 
a wild-type susceptibility,[14,29,31] which is supported by experimental models 
of aspergillosis.[6-9,17,18] Surveillance studies indicate that the prevalence of 
azole resistance varies widely between countries,[1,23,32] and there is increasing 
evidence that in addition to patient therapy, environmental exposure to azole 
compounds may be an important route of resistance development.[24,33] The 
most common mechanisms of resistance in A. fumigatus are modifications in 
the cyp51A gene.[20] Cyp51A encodes cytochrome P450 sterol 14α-demethylase 
and is the target for azole drugs. Azoles bind to the heme cofactor located in the 
active site of the cyp51 encoded enzyme, thereby blocking ergosterol synthesis. 
Subsequent ergosterol depletion and the accumulation of unusual toxic sterols 
lead to inhibition of fungal growth.[22,34]
The objective of this study was to investigate the evolution of azole 
resistance development in a series of consecutive A. fumigatus isolates from 
a patient with aspergilloma. In addition, we reviewed the literature for other 
patients with development of resistant A. fumigatus disease.
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Case report
A 48 year old female was diagnosed with tumor necrosis factor (TNF) receptor-
associated periodic syndrome (TRAPS) in 2000. Seven years earlier, she had 
undergone bilobectomy of the right lung because of recurrent bacterial infections, 
including persistent Mycobacterium avium infection. In 2000, she was diagnosed 
with aspergilloma in a cavity of the right lung of the postoperative severely 
retracted right lung. Surgery was precluded due to the destroyed right lung and 
itraconazole (ITC) treatment was initiated. Adequate serum concentrations were 
observed. She was treated from April 2000 to November 2007; in 2007, a decision 
was made to stop ITC treatment, since her computed tomography scan and chest 
X rays repeatedly showed a complete resolution of the aspergilloma, with no sign 
of recurrence over 8 months. In addition, sputum repeatedly remained negative 
for Aspergillus. Over the next year, her condition was stable, until October 2008, 
when Aspergillus was again cultured from the sputum. She was started on ITC 
but was switch in weeks to voriconazole (VRC). That December, posaconazole 
(POS) was given to replace VRC because of an insufficient clinical response. 
However, after several months there was radiological evidence for relapse of 
the aspergilloma and for Aspergillus localization in the left lung. A subsequently 
recovered A. fumigatus isolate cultured from the sputum exhibited a multi azole-
resistant phenotype, and treatment was switched to liposomal amphotericin B 
(L-AMB), which was subsequently given in combination with caspofungin (CAS). 
Despite one month of treatment with L-AMB and CAS, the patient had ongoing 
Aspergillus disease and died because of severe urosepsis caused by extended-
spectrum-β-lactamase-positive Escherichia coli. 
At autopsy, Aspergillus could not be identified in the left lung, despite 
extensive sampling. The right lung was severely fibrotic and showed a cavity 
filled with necrotic material and Aspergillus hyphae on microscopy, but no 
evidence for invasive disease was found.
Materials and methods
Aspergillus fumigatus isolates. From our patient, nine A. fumigatus isolates 
were obtained within a 10-month period (September 2008 to June 2009). All 
isolates were cultured from respiratory samples, and the primary colonies were 
subcultured on agar plates supplemented with azole compounds (ITC, 4 mg/liter; 
VRC, 1 mg/liter; POS, 0.5 mg/liter)[28] as part of a national surveillance study.
[30] Isolates that grew on these agar plates were further analyzed. A previously 
cultured A. fumigatus isolate from this patient with a wild-type phenotype 
was also selected for further investigation. The isolates were identified by 
macroscopic and microscopic examination and ability to grow at 48°C. 
Susceptibility testing. A broth microdilution test was performed according 
to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
reference method.[27] ITC, POS, VRC, and amphotericin B (AMB) were assayed 
over a two-fold concentration range from 16 to 0.016 mg/liter. Visual readings 
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were performed with a reading mirror, and an endpoint of 100% inhibition was 
used to determine the MICs. For interpretation of the azole MICs, the proposed 
breakpoints were used.[32]
Cyp51A sequence analysis and microsatellite genotyping. To isolate DNA, 
isolates were cultured on Sabouraud agar slants. Conidia were harvested and 
added to 200 μl of breaking buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8, 2% Triton 
X-100, 1% sodium dodecyl sulfate, 1 mM EDTA, pH 8) with ~0.1g glass beads 
(diameters, 0.4-0.6 mm). After shaking by vortexing, conidia were incubated 
at 70˚C for 30 min while shaking. Then, 200 μl of phenol-chloroform-isoamyl 
alcohol (25:24:1) was added and samples were incubated for 5 min while they 
were shaken. After centrifugation for 5 min, the upper phase containing the DNA 
was transferred to a new tube. One microliter of DNA was used per PCR.
The cyp51A gene was amplified and subsequently sequenced as 
described previously.[25] The promoter region was amplified using previously 
described primers P-A7 and P-A5[19] and sequenced using the forward primer 
(P-A7). The cyp51B gene and promoter region were ampliﬁed and sequenced 
using primer sets 5’-CCTTTATTCCCTGCGACA-3’/5’-ACGGCAGAATACCCAGAA-3’ 
and 5’-GGAGACTGCACAACAACG-3’/5’-GGAACCAGTGGAAGACCA-3’. To detect 
mutations, the sequences were compared with the cyp51A and cyp51B sequences 
with GenBank accession numbers AF338659 and AF338660, respectively.
From all isolates as well as three unrelated control isolates, six 
microsatellite loci (STRAf 3A, 3B, 3C, 4A, 4B, and 4C) were ampliﬁed as described 
before.[10] The sizes of the fragments were determined, and repeat numbers 
were assigned.[24] Genotypes consisting of the number of repeats for each of 
the six microsatellites were created for all isolates.
Cyp51A sequence alignment and homology model. An alignment of 47 selected 
fungal Cyp51 protein sequences deposited in the NCBI protein database (http://
www.ncbi.nlm.nih.gov/protein) was constructed using the ClustalW2 multiple-
sequence alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The 
Cyp51 sequences (GenBank accession numbers) included those of Ajellomyces 
capsulatus (AAU01158), Aspergillus clavatus Cyp51A (EAW10153), A. clavatus 
Cyp51B (EAW11788), A. ﬂavus Cyp51A (EED56341), A. ﬂavus Cyp51B (EED50354), 
A. fumigatus Cyp51A (EAL90099), A. fumigatus Cyp51B (EAL87096), A. nidulans 
(AAF79204), Blumeria graminis (CAE18091), Blumeriella jaapii (ABE01107), 
Botryotinia fuckeliana (AAF85983), Candida albicans (AAF00598), C. glabrata 
(AAB02329), C. krusei (AAO83898), C. tropicalis (AAA53284), Clavispora lusitaniae 
(ACH87137), Coccidioides posadasii (AAU01157), Cryptococcus neoformans 
(AAF35366), Cunninghamella elegans (Q9UVC3), Eremothecium gossypii 
(Q759W0), Erysiphe necator (AAC49811), Leptosphaeria maculans (AAN28927), 
Monilinia fructicola (AAL79180), Mycosphaerella graminicola (AAF74756), 
Nakaseomyces delphensis (CAO98836), Neosartorya ﬁscheri Cyp51A (EAW25441), 
N. ﬁscheri Cyp51B (EAW19398), Neurospora crassa (EAA34813), Oculimacula 
acuformis (AAF18468), O. yallundae (AAG44831), Penicillium italicum (CAA89824), 
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P. digitatum (CAD27793), P. digitatum Cyp51B (ADO85403), P. marneffei 
Cyp51B (EEA25858), Phanerochaete chrysosporium (ACI23621), Pneumocystis 
carinii (ABG91757), Podosphaera fusca (ACT56506), Saccharomyces cerevisiae 
(AAA34546), Scheffersomyces stipites (ABN68111), Schizosaccharomyces pombe 
(CAA90803), Talaromyces stipitatus (EED21732), Trichosporon asahii (ADN44281), 
Ustilago maydis (CAA88176), Venturia inaequalis (AAF71293), V. nashicola 
(CAC85409), Yarrowia lipolytica (CAG82748), and Zygosaccharomyces rouxii 
(CAR28109). The positions of amino acid substitutions present in the patient 
isolates as well as their equivalents in other fungi were pinpointed into the 
alignment.        
Furthermore, the locations of the observed amino acid substitutions 
were investigated with the help of a recently published homology model of the 
A. fumigatus Cyp51A enzyme.[25]
A. fumigatus transformations. Transformation experiments were performed as 
described before.[26] Briefly, site-directed mutagenesis was used to introduce 
the point mutations into a cassette containing the cyp51A gene and promoter 
region together with a hygromycin selection marker gene. Mutagenic primers 
5’-CTGGACAAGGGCTTTACTCTCATCAATTTTATGCTACCG-3’ / 5’-CGGTAGCATAA
AATTGATGAGAGTAAAGCCCTTGTCCAG-3’ (for P216L) and 5’-GCTTTACTCCCAT
CAATATTATGCTACCGTGGGCC-3’ / 5’-GGCCCACGGTAGCATAATATTGATGGGAGT
AAAGC-3’ (for F219I) were used. Both cassettes containing either the P216L- 
or F219I-causing mutation were used for homologous gene replacement by 
electroporation in a cyp51A wild-type isolate. Recombinants were selected on 
hygromycin-containing medium and subcultured for further investigation. In 
addition, a cassette without any mutation in the cyp51A gene was incorporated 
by electroporation as a transformation control. The complete cassette was 
sequenced to confirm the presence of the mutation and to ensure that no 
other mutations were present. To confirm that only one copy of cyp51A was 
incorporated, Southern blotting was performed. The susceptibility profile of the 
recombinants, the transformation control, and the transformation
recipient isolate were determined by the EUCAST broth microdilution test as 
described above.
Literature review. We reviewed the literature for cases with acquired azole 
resistance development in A. fumigatus isolates during azole therapy. Only 
patients from whom at least one isogenic susceptible isolate was obtained were 
included, because in these cases it is very likely that resistance was acquired 
during treatment and not obtained from the environment. Information on 
Aspergillus disease, age, sex, underlying disease(s), treatment regimen, the 
number of isolates, the time needed for resistance to develop, and the resistance 
mechanisms observed was collected.
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Results
Characterization of patient isolates. Results of susceptibility testing 
of the nine isolates obtained from our patient are shown in Table 1, 
together with Cyp51A substitutions and the number of repeats for 
each microsatellite maker. Microsatellite typing showed identical 
genotypes for all isolates, indicating that the collection of isolates was isogenic.
The unrelated control isolates showed aberrant genotypes (data not shown). 
The first isolate showed a wild-type susceptibility phenotype, while all 
other isolates showed an ITC MIC of >16 mg/liter. VRC MICs varied between 0.5 
and 8 mg/liter, and POS MICs were between 0.063 and >16 mg/liter. In total, 
four different azole susceptibility profiles were observed. cyp51A sequence 
analysis showed a conversion of alanine (A) to threonine (T) at codon 9 
(codon 9 was changed from GCC to ACC) in all isolates. All eight isolates with 
a non-wild-type azole susceptibility profile had an additional point mutation 
in the cyp51A gene. Six isolates showed a point mutation resulting in the 
substitution of phenylalanine (F) for isoleucine (I) at codon 219 (change of 
codon 219 from TTT to ATT). One isolate contained a mutation at codon 
216 (changed from CCC to CTC), resulting in the replacement of proline (P) 
by leucine (L). The last isolate contained a point mutation leading to the 
substitution of glycine (G) for glutamic acid (E) at codon 54 (GGG was changed 
to GAG). No mutations in cyp51B were observed in any of the nine isolates. 
Cyp51 sequence alignments and homology model. The Cyp51A amino acid 
substitutions observed in the patient isolates were studied in more detail. Cyp51 
sequence alignments (Figure 1) showed that residue A9 is not well conserved. In 
contrast, G54, P216, and F219 are highly conserved within the fungal kingdom. 
Table 1. Isolates obtained from the patient suffering from pulmonary aspergilloma.
MIC (mg/liter) Microsatellite no. of repeats
Isolate 
no.
Date of isolation 
(day-mo-yr) Specimen
 
Cyp51A  
substitution ITC VRC POS AMB 3A 3B 3C 4A 4B 4C Treatment
v74-61 29-9-2008 Sputum A9T 0.5 1 0.063 1 13 9 17 8 9 10 ITC
v76-03 17-11-2008 Sputum A9T, F219I >16 1 0.5 1 13 9 17 8 9 10 VRC
v77-41 17-12-2008 Sputum A9T, P216L >16 1 1 1 13 9 17 8 9 10 POS
v79-63 25-2-2009 Sputum A9T, F219I >16 8 >16 1 13 9 17 8 9 10 POS
v80-28 9-3-2009 Sputum A9T, F219I >16 8 >16 1 13 9 17 8 9 10 POS
v80-55 19-3-2009 Sputum A9T, F219I >16 8 >16 1 13 9 17 8 9 10 POS
v82-58 16-5-2009 Sputum A9T, F219I >16 4 >16 1 13 9 17 8 9 10 POS
v83-11 5-6-2009 Sputum A9T, F219I >16 4 >16 1 13 9 17 8 9 10
L-AMB 
CAS
v83-14 7-6-2009 BAL A9T, G54E >16 0.5 1 1 13 9 17 8 9 10
L-AMB 
CAS
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Figure 1. Alignment of fungal Cyp51 proteins. In case Cyp51 was specified as either 
Cyp51A or Cyp51B, this is indicated after the name of the fungus. The positions of A. 
fumigatus A9, G54, P216, and F219 are indicated in black; aligned positions in the other 
fungal species are indicated in gray. For each of the amino acids we are interested 
in, only 10 amino acids of surrounding sequence is added to the alignment. Other 
surrounding sequence is indicated by ***. The A. flavus Cyp51B sequence was relatively 
short compared to the other sequences. The alignment of A. flavus Cyp51B started at 
the position of residue 55 in A. fumigatus Cyp51A, so there is no comparable amino acid 
for A. fumigatus A9 and G54 in A. flavus Cyp51B.
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Only C. posadasii showed a different amino acid at the position similar to A. 
fumigatus P216.
Because A9T is not well conserved and is also observed in the susceptible 
patient isolate and G54E is already described as being a cause of azole resistance 
[11], we focused on the P216L and F219I substitutions. To check for the position 
of these amino acids in the Cyp51A enzyme, P216L and F219I were pinpointed 
into a Cyp51 homology model. The model showed that both amino acids were 
located close to the opening of one of the two ligand access channels of the 
Cyp51 protein (Figure 2).
A. fumigatus recombinants. A. fumigatus recombinants were constructed 
with either the P216L or the F219I substitution. None of the recombinants 
had additional mutations in cyp51A, the promoter region, the 3’ region, or the 
hygromycin selection marker gene. Southern blotting confirmed that integration 
occurred at a single chromosomal locus in all recombinants (data not shown). 
As shown in Tables 1 and 2, the P216L recombinant exhibited a susceptibility 
phenotype similar to that of patient isolate v77-41, with resistance to ITC and 
Figure 2. Locations of residues 
P216 and F219 indicated in the 
Cyp51A homology model. The 
green tubes represent the two 
ligand access channels leading to 
the heme center of the enzyme. 
    
    
  
Base change in cyp51Aa MIC (g/ml)
Isolate Codon 216 Codon 219 ITC VRC POS
Transformation recipient isolate CCC TTT 0.5 0.5 0.063
Transformation control CCC TTT 0.5 0.5 0.063
Recombinant P216L CTC TTT >16 0.5 1
Recombinant F219I CCC ATT >16 0.5 1
 
Table 2. MICs of recombinants with either the P216L or F219I substitution compared to 
those of the recipient isolate and the transformation control isolate.
a Bold indicates the base change.
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an elevated MIC of POS. The phenotype of the F219L recombinant was similar 
to that of patient isolate v76-03 but different from the phenotypes of five other 
patient isolates with the F219I substitution (v79-63, v80-28, v80-55, v82-58, and 
v83-11) that were cultured later in the course of the disease.
Previously described cases of acquired azole resistance. Including the 
present case, eight cases with acquired azole resistance caused by A. fumigatus 
have been described (Figure 3). From each patient, between two and nine 
isogenic or nearly isogenic isolates of A. fumigatus were obtained, and the first 
isolate(s) showed a wild-type azole susceptibility phenotype. Except for patient 
7, the cyp51A gene was sequenced and mutations at codons G54 (8 isolates from 
5 patients), M220 (2 isolates from 2 patients), G448 (2 isolates from 2 patients), 
P216 (1 isolate), and F219 (6 isolates) were found. In five out of these seven cases, 
multiple resistance mechanisms emerged (patients 1, 3, 5, 6, and 8). All patients 
had azole exposure before the identification of the first resistant isolate. The 
antifungals used for therapy included ITC in two patients (patients 1 and 6), and 
in all other patients, multiple antifungal treatments had been used (Figure 3), 
mainly because of the development of resistance. The patient that we present 
Figure 3. Reported cases of acquired azole resistance in A. fumigatus.[2,3,5,6,14] The 
treatment schedules of all eight patients are indicated with bars, and the A. fumigatus 
isolates obtained from the patients are indicated with triangles. The corresponding 
resistance mechanisms are also indicated. wt, azole-susceptible wild-type isolate; ?, 
resistant isolate without any cyp51A mutations; ND, cyp51A sequence not determined; 
ITC, itraconazole; VRC, voriconazole; CAS, caspofungin; POS, posaconazole; AMB, 
amphotericin B (in various formulations). In the isolates marked with an asterisk, the 
F219I resistance mechanism was found in cyp51A. However, this isolate continued to 
evolve further azole resistance by an additional and yet unknown non-cyp51A-related 
resistance mechanism. Information regarding the treatment of patients 1, 2, and 3 was 
kindly provided by the author (S. Howard, personal communication).
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here also underwent multiple therapy changes, as described above. The time 
between the last culture of an isolate with a wild-type susceptibility phenotype 
and the first with an azole-resistant phenotype varied between 3 weeks and 23 
months (median, 4 months).
Discussion
Azole resistance has been reported to emerge in patients with chronic pulmonary 
aspergillosis and pulmonary aspergilloma during azole therapy. Here, we 
describe a patient with pulmonary aspergilloma from whom isogenic azole-
resistant A. fumigatus isolates with various resistance phenotypes were cultured 
during azole therapy. The resistant isolates showed different mutations in the 
cyp51A gene resulting in G54E, P216L, and F219I substitutions. In addition, all 
isolates contained a mutation leading to the A9T substitution. It is unlikely that 
this mutation will have an impact on azole susceptibility because the sensitive 
isolate also contained the A9T substitution and A9 is not well conserved among 
fungal species. Mutations at codon G54 are already known to be associated with 
azole resistance in A. fumigatus[5,11,12,16,21] and are even mentioned to be hot-
spot mutations[13] because mutations at this site are commonly found in azole-
resistant isolates. Clinical and laboratory-induced mutant A. fumigatus isolates 
with the G54E substitution in Cyp51A usually show the following susceptibility 
profile: ITC MIC, >8 mg/liter; VRC MIC, 0.25 to 0.5 mg/liter; and POS MIC, 1 mg/
liter.[11,12,16] This profile is consistent with that of the isolate obtained from our 
patient. The Cyp51A P216L substitution was described before in a patient with 
chronic cavitary pulmonary aspergillosis with aspergilloma treated with ITC.[14] 
However, this substitution is not yet confirmed to be a cause of resistance by the 
construction of recombinants. To our knowledge, the F219I substitution has not 
been described before.
Sequence alignments revealed that residues P216 and F219 are 
conserved within the fungal kingdom, and the Cyp51A homology model showed 
that they are both located close to the opening of the ligand access channel, 
suggesting that these residues are important. As the channels are thought to be 
used by azole compounds to enter the active site of the protein, mutations at 
codons P216 and F219 might affect the docking of azole molecules. Previously, 
docking of azoles in a homology model of A. fumigatus Cyp51A showed an 
interaction of P216 and several other closely situated residues with POS but not 
with VRC,[34] indicating that mutations in this region might play a role in POS 
resistance. We confirmed the Cyp51A P216L and F219I substitutions to be the 
cause of azole resistance by the generation of recombinants in which the wild-
type cyp51A gene was replaced by a cyp51A cassette containing either one of the 
two mutations. This resulted in resistance to ITC and POS, while recombinants 
remained susceptible to VRC. For P216L, this was in agreement with the 
phenotype of the clinical isolate, but for F219I, only one of six clinical isolates 
harboring this substitution showed a similar phenotype. For the remaining F219I 
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isolates, the VRC MIC had increased from 1 mg/liter to 8 mg/liter and the POS 
MIC had increased from 0.5 mg/liter to >16 mg/liter. As no additional cyp51A 
mutations were found in these five isolates, we assume that a second resistance 
mechanism not related to the cyp51A gene had evolved during POS treatment. 
This is reasonable because resistance mechanisms other than cyp51A mutations 
have been reported before in A. fumigatus.[2,4,14]
Review of the literature revealed seven other cases of aspergillosis 
caused by A. fumigatus in which azole resistance emerged during azole therapy. 
Because we selected only for cases in which at least one isogenic isolate with 
a susceptible phenotype was obtained, it is very likely that resistance was 
induced in the patient. The patients were probably initially colonized or infected 
with a susceptible isolate, and over time, through azole exposure, resistance 
developed in this initial isolate. In one case, the resistance mechanisms 
were not determined, but in five of the remaining seven cases (71%), at least 
two resistance mechanisms emerged, indicating that different evolutionary 
processes within one patient might result in independent adaptation of the 
fungus to azole exposure. Furthermore, in the case described here, resistance 
might also have accumulated sequentially as one of the resistant isolates further 
evolved to become multiazole resistant.      
 All patients were diagnosed with aspergilloma and chronic pulmonary 
aspergillosis. It was previously suggested that in the case of aspergilloma or 
cavitary aspergillus disease, the fungus is able to undergo multiple generations 
in the patient by the asexual way of reproduction. Sporulation (in the lung) as 
opposed to hyphal growth may be important to facilitate the expression of the 
azole-resistant phenotype; hyphal growth is typically found in acute invasive 
aspergillosis.[33]         
 Our literature review showed that the median time between the last 
cultured wild-type isolate and the first azole-resistant strain was only 4 months, 
indicating that resistance can be induced soon after initiating treatment. We 
have to address that two of the patients (patients 4 and 8; Figure 3) received 
azole treatment for several years before the last cultured wild-type isolate 
was obtained. It is therefore possible that under azole pressure a preceding 
event unrelated to cyp51A occurred in the wild-type isolate and that the event 
subsequently resulted in the rapid acquisition of the resistance mutations. 
From every clinical sample, only one colony is usually subcultured, stored, and 
subjected to susceptibility testing even when more colonies grow. Therefore, it 
cannot be excluded that the resistance mechanisms found persisted for a longer 
time. Moreover, additional resistance mechanisms may have been found when 
multiple colonies had been tested. Furthermore, patients are not usually regularly 
sampled for the presence of fungi, so isolates cultured could have already been 
present in the patient for a long time. Although it is now shown that azole 
resistance can be induced in the patient within a relatively short period of time, 
the questions of which proportion of azole-treated patients with aspergilloma 
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or other cavitary lung lesions develop azole resistance and whether specific risk 
factors for resistance development can be identified remain.    
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Abstract
The prevalence and spread of azole resistance in clinical Aspergillus fumigatus 
isolates in the Netherlands are currently unknown. Therefore, we performed a 
prospective nationwide multicenter surveillance study to determine the effects 
of resistance on patient management strategies and public health. From June 
2007 through January 2009, all clinical Aspergillus spp. isolates were screened 
for itraconazole resistance. In total, 2,062 isolates from 1,385 patients were 
screened; the prevalence of itraconazole resistance in A. fumigatus in our patient 
cohort was 5.3% (range 0.8%–9.5%). Patients with a hematologic or oncologic 
disease were more likely to harbor an azole-resistant isolate than were other 
patient groups (p<0.05). Most patients (64.0%) from whom a resistant isolate 
was identified were azole naive, and the case-fatality rate of patients with azole- 
resistant invasive aspergillosis was 88.0%. Our study found that multiazole 
resistance in A. fumigatus is widespread in the Netherlands and is associated 
with a high death rate among patients with invasive aspergillosis.
Introduction
Azoles are the primary class of antifungal agents used for evidence-based 
treatment and prevention of Aspergillus spp. diseases.[1] Azoles are the 
only class of mold-active agents that can be used orally, and voriconazole 
and posaconazole have improved the survival of patients at risk for invasive 
aspergillosis.[2-5] However, recent reports describe the emergence of acquired 
resistance of Aspergillus spp. to azole compounds.[6-16] Azole resistance 
may develop in patients with cavitary lung lesions, such as aspergilloma, or 
in patients with allergic bronchopulmonary aspergillosis who are  treated 
with mold-active azoles, most notably, itraconazole.[7,17] In these patients, 
resistance is most commonly observed in Aspergillus fumigatus, and the isolates 
may be resistant to only itraconazole (ITZ) or exhibit a multi-azole- or pan-azole-
resistant phenotype. The phenotype depends on the underlying resistance 
mechanism, which commonly involves point mutations in the cyp51A-gene, 
the target for antifungal azoles.[6-8,10,11,17-21] A wide range of mutations 
was found in azole-resistant Aspergillus spp. isolates that were cultured from 
clinical samples from patients treated with azoles, and individual azole-
resistant Aspergillus spp. colonies harbored different resistance mechanisms.[7] 
 In the Netherlands, a highly dominant resistance mechanism was found in 
isolates from epidemiologically unrelated patients.[6,9] The dominant resistance 
mechanism consisted of a substitution of leucine for histidine at codon 98 of the 
cyp51A-gene in combination with a 34-bp tandem repeat in the promoter region 
of this gene (TR/L98H).[6,11] The corresponding phenotype showed resistance 
to itraconazole and intermediate susceptibility or resistance to voriconazole, 
posaconazole, or both.[6,20] TR/L98H isolates were recovered from azole-
treated and azole-naïve patients with Aspergillus spp. diseases.[6,9,10,22-24] 
Azole resistance may be associated with a high probability of azole treatment 
failure, a possibility that is supported by preclinical evidence.[7,9,22-26] 
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 On the basis of the above-mentioned observations, we hypothesized 
that resistance might have emerged as a consequence of exposure of A. 
fumigatus to azole fungicides in the environment.[27] Preliminary studies 
indeed showed that A. fumigatus isolates harboring TR/ L98H could be 
recovered from the environment.[28,29] Furthermore, TR/L98H isolates were 
cross-resistant to certain azole fungicides.[27,28]    
 The spread and prevalence of azole resistance in clinical A. fumigatus 
isolates are unknown. Various studies in the Netherlands that have analyzed 
Aspergillus spp. culture collections indicate that the prevalence ranges from 
1.8% to 12.8%.[6,30,31] Obtaining insight into the spread of azole resistance is 
essential for determining the implications of resistance for patient management 
strategies and public health. We therefore conducted a prospective surveillance 
study in 7 university medical centers in the Netherlands.
Methods
Study Design. All Aspergillus spp. isolates cultured from clinical samples that 
were processed in the 7 university medical microbiology laboratories were 
routinely screened for the presence of azole resistance, irrespective of the clinical 
relevance of the culture result. The University Medical Centers are located in 7 
different cities in the Netherlands, and clinical isolates were screened during 
a 20-month period (June 2007–January 2009). Patient data were recorded in a 
Web-based database. An online questionnaire was completed for every collected 
isolate. The questionnaire included questions about isolate characteristics 
(species identification and date of isolation) and patient characteristics (age, 
sex, and underlying disease).
Screening ITZ Agar Slants. Aspergillus spp. colonies that grew in primary 
cultures were subcultured on Sabouraud agar slants supplemented with 4 mg/L 
of ITZ and incubated at 35°C–37°C. The colonies’ ability to grow on the ITZ agar 
slants was assessed after 48 hours of incubation. For every isolate that was able 
to grow on the ITZ agar slants (ITZ positive), the primary culture isolate was sent 
to the Radboud University Nijmegen Medical Center for further analysis. Isolates 
that failed to grow on the ITZ agar slants (ITZ negative) were not analyzed. 
However, for all isolates that were screened, the online questionnaire was 
completed. At the screening sites, the Aspergillus spp. isolates were identified to 
species level by conventional methods, i.e., thermotolerance and macroscopic 
and microscopic assessment of culture morphologic features.
Proficiency Testing. The ITZ agar slants were prepared at the Radboud University 
Nijmegen Medical Center and distributed to the other medical microbiology 
laboratories. Each center was provided with a protocol and a set of 6 A. fumigatus 
isolates. Four isolates were resistant to ITZ (MIC >16 mg/L), while 2 were susceptible 
(ITZ MICs 0.125 and 0.25 mg/L). The centers were blinded for the resistance profiles 
and were asked to determine the ability of the isolates to grow on the ITZ agar 
slants.           
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Analysis of ITZ-positive Isolates. Every ITZ-positive isolate was analyzed for 
certain phenotypic and genotypic features. The phenotypic analysis included 
the morphologic features of the isolate and susceptibility testing according to 
established standards[32] by using a broth microdilution format. MICs were 
determined for ITZ, voriconazole, and posaconazole. Genotypic analyses were 
performed by complete sequencing of the cyp51A gene by using the reference 
sequence of strain no. AF338659 from GenBank.   
 For the confirmed ITZ-positive isolates, additional patient data that 
included azole exposure <3 months before the date of isolation of the resistant 
isolate and the presence of Aspergillus spp. disease were requested from 
the treating physician. Patients with cancer and invasive aspergillosis were 
classified according to the revised European Organization for Research and 
Treatment of Cancer/Mycoses Study Group definitions.[33] In addition, patient 
data were collected on treatment and outcome 3 months after diagnosis. 
Statistical Analysis. Statistical analyses were performed by using SPSS version 
17.0 (IBM, Somers, NY, USA). Analyses consisted of χ2 tests and a calculation of 
the κ coefficient.  
Results  
Proficiency Testing. Four of 6 control A. fumigatus isolates were resistant 
to ITZ and expected to grow on the ITZ agar slants, while the remaining 2 
isolates were ITZ susceptible and should not grow on the ITZ agar slants. 
The 4 isolates with the azole- resistant phenotype harbored the TR/L98H 
resistance mechanism. For 3 ITZ-positive and the 2 ITZ-negative isolates, 
100% agreement was found between the 7 centers. For 1 ITZ-positive isolate, 
the assessment of growth on the ITZ agar slant was incorrect from 3 centers; 
this isolate was a slowly sporulating A. fumigatus isolate. The κ coefficient 
calculated to assess the reproducibility of the method was 0.81.[34]   
Mycology. During June 2007 through January 2009, we screened 2,062 
Aspergillus spp. isolates from 1,385 patients for azole resistance using the ITZ 
agar slants. Most isolates were identified as A. fumigatus (1,792/2,062 [86.9%]) 
(Table 1). For 50 (2.5%) Aspergillus spp. isolates, species identification was not 
done. Most Aspergillus spp. isolates were isolated from respiratory samples; 
1,461 of 2,062 (70.9%) were from sputum cultures, and 60 (2.9%) were from 
cultures derived from clinical specimens obtained from sterile sites (i.e., tissue 
specimens obtained through invasive procedures or at autopsy) (Table 1).  
 Ninety isolates were able to grow on the ITZ agar slants and were sent 
to the Radboud University Nijmegen Medical Center for further analyses. In vitro 
susceptibility testing showed that for 84 (93.3%) of 90 ITZ-positive isolates, the 
MIC of ITZ was >2 mg/L, which was considered resistant.[20] Most ITZ-positive 
isolates also exhibited non-wild-type susceptibility profiles to voriconazole 
and posaconazole. A resistant phenotype for voriconazole (>2 mg/L) and 
posaconazole (>0.5 mg/L) was observed in 67/84 (79.8%) and 14/84 (16.7%) of ITZ-
positive isolates, respectively. An intermediate susceptibility profile (2 mg/L for 
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  Source and species  No. (%) susceptible,               No. (%) resistant,
              n = 1,978             n = 84
  Specimen source
 Sputum             1,397 (70.6)                                       64 (76.2)
 Ear swab                 176 (8.9)              3 (3.6)
 BAL fluid     97 (4.9)                                            6 (7.1)
 Bronchus secretion    66 (3.3)              2 (2.4)
 Throat/nasal swab    66 (3.3)              1 (1.2)
 Tissue      55 (2.8)              5 (6.0) 
 Skin swab/nail     38 (1.9)              1 (1.2)
 Mouth wash     26 (1.3)              1 (1.2)
 Pus/wound swab    16 (0.8)              1 (1.2)
 Bronchial wash    11 (0.6)     0
 Feces        8 (0.4)     0
 Unknown     22 (1.1)     0
  Species
 A. fumigatus             1,710 (86.5)             82 (97.6)
 A. flavus                    98 (5.0)       0
 A. niger              52 (2.6)                 2 (2.4)
 A. terreus     35 (1.8)     0
 A. nidulans     14 (0.7)     0
 A. versicolor     13 (0.7)     0
 A. glaucus       6 (0.3)     0
 Unknown                    50 (2.5)     0
*BAL, bronchoalveolar lavage.
Table 1. Characteristics of screened susceptible and resistant isolates of Aspergillus 
spp., the Netherlands, 2007–2009*
                 Median MIC, mg/L (range)
No. isolates      Mutations in the Cyp51A gene           Itraconazole          Voriconazole        Posaconazole
74    TR/L98H†             >16 (16–>16)    8 (1–16)  0.5 (0.25–2) 
1    G54W†                     >16                          0.5         >16
1    P216L†                 16           2          0.5
1    F219I†                    >16                      0.25         0.25 
1    Series‡                     >16                      >16           1
4    None                            >16 (16–>16)   4 (0.5–4)          0.2 (0.125–1)
In vitro susceptibility testing was performed according to the Clinical and Laboratory 
Standards Institute M38A2 method (32).
†Mutations that have previously been shown to be associated with azole resistance in A. 
fumigatus (7,20,21).
‡Series of mutations in Cyp51A-gene: F46Y, G89G, M172V, N248T, D255E, L358L, E427K, 
and C454C (8).
Table 2. Characteristics of itraconazole-positive Aspergillus fumigatus isolates, the 
Netherlands, 2007–2009*
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voriconazole and 0.5 mg/L for posaconazole) was observed in 12/84 (14.3%) and 
44/84 (52.4%) of ITZ-positive isolates, respectively (Table 2).[20]  
 Sequence-based identification classified 82 ITZ-positive isolates as A. 
fumigatus and 2 as A. niger. Sequencing of the cyp51A gene showed a substitution 
of leucine for histidine at codon 98 in combination with a 34-bp tandem repeat 
in the gene promoter in 74 (90.2%) of 82 resistant A. fumigatus isolates (Table 2). 
Other cyp51A mutations were found in 3 isolates (substitutions G54W, P216L, and 
F219I) (Table 2).[7,8,20,21] In 1 isolate, a series of mutations was found, and in the 
remaining 4 azole-resistant A. fumigatus isolates (4.9%), no mutations were found 
in the cyp51A gene.[8] Because A. niger has no known resistance mechanisms, 
the 2 azole-resistant A. niger isolates were not further analyzed.   
Prevalence of Azole Resistance. A median of 100 isolates were screened 
each month, with a range of 78–140 isolates per month. The total number of 
screened clinical isolates per center ranged from 130 to 449 and were recovered 
from 84 to 238 patients. The collection of isolates over the study period and the 
distribution of the recovery of resistant isolates are shown in Figure 1. Overall, 
82 (4.6%) of 1,792 screened A. fumigatus isolates were azole resistant. The per-
patient analysis showed a prevalence of 5.3%. Figure 2 shows the prevalence 
of resistance in A. fumigatus per center. The prevalence of azole resistance in 
A. niger was 3.8%. No seasonal variation was observed.    
Figure 1. Number of screened Aspergillus spp. isolates per month (bars) and prevalence 
(%) of azole resistance (line), the Netherlands, 2007– 2009. ITZ, itraconazole.  
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Patient Characteristics. The screened A. fumigatus isolates were cultured 
from 1,192 patients, while other Aspergillus spp. isolates were recovered from 
193 patients. Among the patients who harbored A. fumigatus isolates, the 
predominant underlying diseases were cystic fibrosis (382/1,192 [32.1%]) and 
other pulmonary diseases (265/1,192 [22.2%]). Almost 12% (138/1,192) of the A. 
fumigatus isolates were from patients who had hematologic/oncologic diseases. 
The distribution of underlying diseases is shown in Table 3.    
Characteristics of Patients with Azole-Resistant Isolates. The 82 confirmed 
ITZ-resistant A. fumigatus isolates were recovered from 63 patients. The patients’ 
ages ranged from 1 to 85 years, with a mean age of 48.9 years. The sex distribution 
was equal.          
 Overall, the distribution of underlying diseases in patients with an ITZ-
resistant isolate was similar to that observed in the group with ITZ-susceptible 
isolates, with 1 exception. In the group of patients with ITZ-resistant isolates, 
significantly more patients had hematologic/oncologic diseases than in the 
group that harbored ITZ-susceptible isolates (13/63 [20.6%] and 125/1,129 
[11.1%], respectively; p<0.05; Table 3).      
 Aspergillus disease caused by an ITZ-resistant isolate was diagnosed 
in 23 patients (36%). Invasive aspergillosis was diagnosed in 8 patients 
(13%), 6 with confirmed and 2 with probable cases (Table 4). Four of these 
patients were azole naive, and 1 patient had been previously treated with 
fluconazole, which has no activity against Aspergillus species. All A. fumigatus 
isolates from patients with azole-resistant invasive aspergillosis harbored 
the TR/L98H resistance mechanism (Table 4). All 5 patients who were 
treated with voriconazole monotherapy died within 3 months of receiving 
a positive culture result. For 3 patients, voriconazole therapy was switched 
to another class of antifungal compounds, i.e., echinocandin, polyene, or 
both, but only 1 of those 3 patients survived. Overall, 7 (87.5%) of 8 patients 
with azole-resistant aspergillosis died within 3 months (Table 4).   
 Noninvasive Aspergillus spp. disease with an ITZ-resistant isolate 
was diagnosed in 15 patients. Five patients had cystic fibrosis and allergic 
bronchopulmonary aspergillosis. Six patients had an aspergilloma; of these 
patients, 2 were immunocompromised, 1 because of AIDS and 1 because of 
Job syndrome. Three patients sought treatment for otomycosis; 1 patient had 
Aspergillus spp. sinusitis. Data on previous exposure to azoles were available 
for 14 patients with noninvasive Aspergillus spp. disease; and 9 (64.2%) of these 
patients were azole naive. The TR/ L98H mutation was the dominant resistance 
mechanism, because it was present in 12 (80%) of 15 isolates. Overall, 14 (64.3%) 
of 22 patients with azole-resistant Aspergillus spp. disease and known status of 
azole exposure were azole naive at the time the resistant isolate was cultured. 
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Discussion
Azole resistance is widespread in clinical A. fumigatus isolates in the Netherlands, 
and resistant isolates were found at all participating university medical centers. 
The overall prevalence was 5.3%, which is in a similar range as observed in the 
fungus culture collection of the Radboud University Nijmegen Medical Center.[6] 
However, the prevalence varied widely between the centers, with 1 center 
showing azole resistance in 10 (9.5%) of 105 patients with a positive Aspergillus 
spp. culture. In a previous study, we reported a resistance prevalence of 12.8% 
among A. fumigatus isolates sent to our department by other hospitals in the 
Netherlands.[6] This higher resistance rate may have been due to a different 
selection of isolates. In this study, all Aspergillus spp. isolates cultured in the 
participating laboratories were screened for resistance, irrespective of their 
clinical relevance, while in our previous study the isolates that were sent to 
Nijmegen were from patients with Aspergillus spp. diseases for whom antifungal 
therapy was not successful.[6]  
 Two other studies have investigated the prevalence of azole resistance in 
Aspergillus spp. in the Netherlands. One study investigated a collection of 170 
clinical A. fumigatus isolates recovered from 114 patients from 21 different 
medical centers in 1945–1998.[30] Three (1.8%) isolates were resistant to ITZ and 
were later found to harbor the TR/L98H resistance mechanism. These were the 
first TR/L98H isolates recovered in the Netherlands.[6] Another study investigated 
the prevalence of azole-resistant Aspergillus spp. isolates in the Netherlands by 
Figure 2. Prevalence (%) of azole-
resistant Aspergillus fumigatus 
infections in university medical 
centers, the Netherlands, 2007–
2009.    
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using a collection of 209 unselected clinical A. fumigatus isolates obtained over a 
6-month period in 2005.[31] Only 4 azole-resistant isolates were found, which 
corresponds with a prevalence of 1.9%.[31] The low prevalence may be because 
of the methods used. We used ITZ-containing agar-slants to select for resistant 
isolates, which enables detection of resistant colonies even in the presence of 
multiple azole-susceptible colonies. Although Klaassen et al.[31] did not explain 
how isolates were obtained, azole-resistant colonies could have been missed if 
regular culture media were used.[22,31] A k coefficient of 0.81 indicates that 
screening for azole resistance by using agar supplemented with ITZ is a highly 
reproducible method and appears to be a feasible approach for screening for 
azole resistance and for surveillance studies.[34]  
 Most (74/82 [90.2%]) of the azole-resistant isolates in our study were 
found to possess the TR/L98H mutation in the cyp51A-gene, which is a similar 
proportion as reported previously.[6] Previous studies have suggested that the 
probability of 2 genomic changes developing during azole therapy is highly 
unlikely and that exposure of A. fumigatus to azoles in the environment may be 
a possible route of resistance development.[6,27,28] A. fumigatus isolates 
harboring the TR/L98H resistance mechanism were recovered from the 
environment and were genetically related to TR/L98H-containing clinical 
isolates.[28] This mode of resistance development implies that previous 
exposure of patients to azole compounds is not a prerequisite. Indeed, our study 
shows that 64% of patients with an azole-resistant isolate have no history of 
previous azole exposure during the 3 months before culturing the isolate. This 
finding supports the proposed environmental route of resistance development. 
 The prevalence and spread of TR/L98H in A. fumigatus in other countries 
are largely unknown. A recent study by Mortensen et al. showed that 8% of 
environmental A. fumigatus isolates in Denmark harbored the TR/L98H resistance 
mechanism, which indicates that TR/L98H may be spreading.[29] Because in 
vitro susceptibility testing of A. fumigatus is not routinely performed in most 
laboratories, international surveillance studies are warranted.  
 Most TR/L98H isolates were resistant to voriconazole (79%), but a broad 
range of MICs was observed that varied from 1 mg/L to 16 mg/L. Reasons for this 
variation remain unclear. TR/L98H isolates may have developed additional 
mutations that confer voriconazole resistance but that are not associated with 
the cyp51A gene. Another possibility is that the tandem repeat, which serves as a 
transcriptional enhancer, causes varying levels of up-regulation of the cyp51A 
gene. This up-regulation may result in differences in the voriconazole phenotype. 
More research is needed to gain insight into this phenomenon.  
 The outcome for patients with azole-resistant invasive aspergillosis was 
dismal, with a mortality rate of 88%. None of the patients who were treated with 
voriconazole monotherapy were alive at 3 months; of 3 patients whose treatment 
was switched to another class of antifungal drugs, only 1 survived. A critical 
issue for future study is whether azole resistance is a determinant of the poor 
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clinical outcome of patients with azole-resistant aspergillosis. A previously reported 
case series of patients with primarily noninvasive Aspergillus spp. disease indicated 
that azole resistance was associated with treatment failure.[7] However, 
establishing a relation between resistance and treatment outcome in invasive 
aspergillosis is complex because of the multiple factors that contribute to treatment 
outcome, including underlying disease, drug exposure, timing and accuracy of 
diagnosis, and timing of antifungal therapy. Furthermore, data are lacking on the 
effects of in vitro susceptibility patterns of Aspergillus spp. isolates on treatment 
outcomes. This relationship was recently described by using Aspergillus spp. 
isolates recovered from patients enrolled in the Transplant-Associated Infection 
Surveillance Network.[35] The 12-week mortality rate for patients with culture-
positive confirmed or probable invasive aspergillosis was 53%.[35] For patients 
with azole-susceptible A. fumigatus aspergillosis treated with voriconazole, the 
proportion of deaths was 48% (J.W. Baddley, pers. comm.).  
 In a study by Herbrecht et al.[2], a subset of 51 modified-intent-to-treat 
patients with definite (43 patients) or probable (8 patients) invasive aspergillosis 
had a positive culture with A. fumigatus with a wild-type susceptibility. The all-
cause proportion of deaths in this group at 12 weeks was 39% (P. Troke, pers. 
comm.). Both these analyses show a lower death rate than observed in our study, 
which indicates that azole resistance may be associated with a poor outcome. The 
median MIC of voriconazole in the 8 patients with azole-resistant invasive 
aspergillosis was 4 mg/L, which is resistant.[20] Effects of an elevated voriconazole 
MIC on treatment outcome were supported by preclinical experimental results, in 
which mice infected with an A. fumigatus isolate that had a voriconazole MIC of 2 
mg/L required a 2-fold higher voriconazole dose than did mice infected with a wild-
type isolate to achieve a comparable survivalrate.[25]   
 The low survival rate of patients whose treatment was switched from azole 
therapy to nonazole therapy could be due to the delay of initiation of treatment 
with an effective alternative drug or to the presence of cerebral disease. Overall, 
the number of patients with azole-resistant aspergillosis in our study was low, and 
additional studies are needed to confirm the relation between azole resistance and 
treatment failure.   
 Because specimens from patients with invasive aspergillosis seldom 
produce positive cultures, our study underestimates the number of azole-resistant 
cases. The diagnosis of azole resistance in culture-negative cases is a challenge 
because current biomarkers, such as galactomannan and 1,3-β-D-glucan, do not 
enable species identification, let alone in vitro susceptibility testing. Molecular 
tools have been shown to be able to detect mutations associated with azole 
resistance directly in tissue[36] or in respiratory specimens[37] but are not yet 
suitable for use in routine patient care. Molecular tools need to be developed that 
enable the rapid detection of multiple mutations, although only known mutations 
can be detected.   
 Our study shows that azole resistance in clinical A. fumigatus isolates is 
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widespread in the Netherlands and that the survival rate of patients with azole-
resistant invasive aspergillosis is low. The dominance of the TR/L98H resistance 
mechanism and the high proportion of resistant isolates recovered from azole-
naive patients support an environmental route of resistance development. We 
believe that continued surveillance is required in the Netherlands, as well as 
routine in vitro susceptibility testing of A. fumigatus isolates obtained from 
patients with Aspergillus spp. disease. International surveillance programs are 
also warranted to estimate the size of the emerging problem of azole resistance. 
Furthermore, the first-line therapy of patients with invasive aspergillosis should 
be reconsidered, at least in those centers with a high prevalence of azole 
resistance.
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Abstract  
Background. Azole resistance is an emerging problem in Aspergillus fumigatus 
and complicates the management of patients with Aspergillus-related diseases. 
Selection of azole resistance may occur through exposure to azole fungicides in 
the environment. In the Netherlands a surveillance network was used to 
investigate the epidemiology of resistance selection in A. fumigatus.   
Methods. Clinical A. fumigatus isolates were screened for azole resistance in 8 
university hospitals using azole agar dilution plates. Patient information was 
collected using an online questionnaire and azole-resistant A. fumigatus isolates 
were analyzed using gene sequencing, susceptibility testing, and genotyping. Air 
sampling was performed to investigate the presence of resistant isolates in 
hospitals and domiciles.      
Results. Between December 2009 and January 2011, 1315 A. fumigatus isolates 
from 921 patients were screened. A new cyp51A-mediated resistance mechanism 
(TR46/Y121F/T289A) was observed in 21 azole-resistant isolates from 15 patients 
in 6 hospitals. TR46/Y121F/T289A isolates were highly resistant to voriconazole 
(minimum inhibitory concentration ≥16 mg/L). Eight patients presented with 
invasive aspergillosis due to TR46/Y121F/T289A, and treatment failed in all 5 
patients receiving primary therapy with voriconazole. TR46/Y121F/T289A 
Aspergillus fumigatus was recovered from 6 of 10 sampled environmental sites.  
Conclusions. We describe the emergence and geographical migration of a 
voriconazole highly resistant A. fumigatus that was associated with voriconazole 
treatment failure in patients with invasive aspergillosis. Recovery of TR46/Y121F/
T289A from the environment suggests an environmental route of resistance 
selection. Exposure of A. fumigatus to azole fungicides may facilitate the 
emergence of new resistance mechanisms over time, thereby compromising the 
use of azoles in the management of Aspergillus-related diseases.  
 
Introduction  
The medical triazoles itraconazole, voriconazole, and posaconazole are the 
primary antifungal agents currently used in the management of infections 
caused by the saprophytic mold Aspergillus fumigatus. These triazoles are 
clinically licensed for the prevention and treatment of both noninvasive 
Aspergillus diseases as well as invasive aspergillosis.[1] Acquired resistance in A. 
fumigatus has long been perceived as a manageable problem as resistance 
development during azole therapy has been reported with only a very low 
frequency.[2-4] However, culture may underestimate the presence of 
resistance[5], and A. fumigatus isolates that harbor a resistance mechanism are 
commonly resistant to multiple triazoles.[6-9]  
 In the Netherlands, a second route of resistance development was 
suggested in which clinical A. fumigatus isolates may have become resistant 
through environmental exposure to 14α-demethylase inhibitors (DMIs).[6,10-12] 
DMIs inhibit fungal Cyp51A activity and are abundantly used for crop protection 
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and material preservation. Five DMIs, from the triazole class, showed in vitro 
activity against A. fumigatus and were shown to have a molecule structure that 
was highly similar to that of the clinically licensed triazoles.[11] The environmental 
mode of resistance development is of major importance as >90% of Dutch 
clinical azole-resistant isolates are believed to have originated through this 
mode of resistance development.[6,7,12] The ﬁrst resistance mechanism that is 
believed to be of environmental origin consists of a substitution at codon 98 in 
the cyp51A gene in combination with a 34 base-pair tandem repeat in the gene 
promoter (TR34/L98H).  
 TR34/L98H ﬁrst emerged in clinical A. fumigatus isolates from Dutch 
patients in 1998 and a national surveillance study indicated that this resistance 
mechanism is now endemic in Dutch hospitals. Aspergillus-related diseases due 
to TR34/L98H included noninvasive infections and invasive aspergillosis, and 
infections were found to occur both in azole-treated as well as in azole-naive 
patients.[6,7] TR34/L98H is increasingly reported in other European countries, 
and more recently also in China and India.[6,13-23] Molecular typing studies 
indicate that the fungicide-driven route of resistance development carries the 
risk of geographical migration of this resistance trait, similar to azole-resistant 
phytopathogenic fungi.[24]  
 In our current study, we investigated the emergence of a new azole 
resistance mechanism in A. fumigatus. We describe the epidemiology and clinical 
implications, and performed environmental sampling to determine if the new 
resistance mechanism was present in our environment.    
        
Methods  
Surveillance Network. Between May 2009 and January 2011, all Aspergillus 
isolates cultured from clinical samples that were processed in medical 
microbiology laboratories of the 8 university medical centers in the Netherlands 
were routinely screened for the presence of azole resistance, irrespective of the 
clinical relevance of the culture result. An online questionnaire was completed in 
7 of 8 centers for every collected isolate. The questionnaire included questions 
about isolate characteristics (species identiﬁcation and date of isolation) and 
patient characteristics (age, sex, and underlying disease). In one center the 
questionnaire was only completed for patients from whom a resistant isolate 
was recovered.  
Screening: 4-Well Azole-Agar Dilution Plates. Aspergillus colonies that grew in 
primary cultures were subcultured on a specially developed 4-well azole-agar 
dilution (4D) plate.[25] All wells contained Roswell Park Memorial Institute 1640 
agar, and 3 wells were each supplemented with 1 of the azoles: itraconazole (4 
mg/L), voriconazole (1 mg/L), or posaconazole (0.5 mg/L). The fourth well 
contained no azole and served as growth control. The 4D plates were incubated 
at 37°C and growth was assessed after 48 hours. For every isolate that was able 
to grow on any of the azole-containing wells, the primary culture isolate was 
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sent to the Radboud University Nijmegen Medical Centre for further analysis. For 
those isolates that grew only on the control well, the Web-based questionnaire 
was completed, but the isolate was considered azole-susceptible and not further 
analyzed. At the screening sites, the Aspergillus isolates were identiﬁed to the 
species level by conventional methods, that is, the ability to grow at 48°C and 
macro- and microscopic culture morphology.   
Analysis of A. fumigatus Isolates. All A. fumigatus isolates that grew on 1 or 
more azole-containing agar wells were investigated for their antifungal 
susceptibility to itraconazole, voriconazole, posaconazole, and the DMI 
tebuconazole using the Clinical and Laboratory Standards Institute M38-A2 
broth microdilution reference method.[26] For resistant isolates that were 
conﬁrmed to exhibit a non-wild-type phenotype, the full coding sequence of the 
cyp51A gene and promoter region was determined by polymerase chain reaction 
(PCR) ampliﬁcation and sequencing to detect any mutations (reference cyp51A 
sequence: GenBank accession number AF338659).[27] Molecular identiﬁcation 
was performed by sequencing the highly conserved β-tubulin and calmodulin 
gene, as described previously.[28]  
 Microsatellite genotyping was used to investigate genetic distances 
between the isolates by analysis of 6 microsatellites (STRAf 3A, 3B, 3C, 4A, 4B, 
and 4C), as described previously.[6] If multiple resistant isolates were obtained 
from 1 patient, only the ﬁrst isolate was included. For every resistant isolate, 2 
control isolates were selected that had been cultured between 1 month before 
and 1 month after the date of isolation of the resistant isolate. One control isolate 
harbored the TR34/L98H resistance mechanism, whereas the other exhibited a 
wild-type phenotype. From the microsatellite data, allele sharing distance 
matrices were generated and these matrices were used as input for the Neighbor 
program of the PHYLIP software package (Phylogeny Inference Package version 
3.6, Department of Genome Sciences, University of Washington, Seattle) to 
produce the dendrogram.[29]  
Patient Characteristics. The Web-based database was used to retrieve clinical 
information of the patients with a culture yielding A. fumigatus. For patients 
harboring an azole-resistant isolate, the following additional information was 
recorded: the presence of Aspergillus disease, azole exposure within 12 weeks 
preceding the culture of the resistant isolate, treatment, and outcome at 12 
weeks. Invasive aspergillosis was classiﬁed according to the European 
Organizationfor Research and Treatment of Cancer and Mycoses Study Group 
(EORTC/MSG) consensus deﬁnitions.[30] Human experimentation guidelines 
from the Committee on Research Involving Human Subjects Arnhem–Nijmegen 
were followed in the conduct of this research.   
Environmental Sampling. The presence of A. fumigatus resistant to medical 
triazoles in the environment was investigated through sampling at the Radboud 
University Nijmegen Medical Centre, the University Medical Centre Groningen, 
and 8 domiciles (6 in the Nijmegen area and 2 in the Groningen area). Indoor 
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sites and 1 site in the direct outdoor proximity were sampled. Air samples were 
obtained using a Casella air sampler (Casella Measurement, catalog number 
E7627/Z-24, serial number 026510/026514, London, UK). Cultures of airborne 
viable fungi were performed on Sabouraud agar. For selection of azole-resistant 
fungi, Sabouraud agar supplemented with itraconazole (4 mg/L) or voriconazole 
(1 mg/L) were used. The volume of air that was sampled was 14 000 L (700 L/
minute for 20 minutes) to detect azole-resistant spores. The plates were 
incubated at 37°C and inspected twice daily for 4 days.  
 Any colony that grew on the agar supplemented with azoles was 
subcultured on a Sabouraud agar slant and was identiﬁed as A. fumigatus using 
colony morphology and microscopic characteristics. Aspergillus fumigatus 
isolates were screened for the presence of an insertion in the promoter region of 
the cyp51A gene by previously described PCR primers and conditions.[24] 
Tandem repeats of different sizes could be identiﬁed on the basis of the size of 
the ampliﬁed PCR fragment. Isolates containing the TR34 were screened for the 
presence of the L98H substitution by using 2 PCR reactions: an L98- and an L98H-
speciﬁc PCR (primers described elsewhere).[24] Azole-resistant isolates without 
TR34/L98H were selected for sequencing the cyp51A gene and promoter region as 
described above.[27]  
 
Results  
Emergence of the New Resistance Mechanism. In January 2010, a clinical A. 
fumigatus isolate originating from Nijmegen grew on the well containing 
voriconazole, and not on those containing itraconazole or posaconazole. In vitro 
susceptibility testing showed no activity of voriconazole (minimum inhibitory 
concentration [MIC] >16 mg/L), and attenuated activity of itraconazole (MIC 2 
mg/L) and posaconazole (MIC 0.5 mg/L) (Table 1). Sequence analysis of the 
cyp51A gene showed the presence of 2 mutations leading to substitutions Y121F 
and T289A. In addition, a 46 base-pair tandem repeat was found in the gene 
promoter (TR46/Y121F/T289A). A second isolate was cultured in January 2010 
from a patient in Amsterdam that exhibited a similar voriconazole-resistant 
phenotype and identical TR46/Y121F/T289A resistance mechanism (Table 1).  
 The culture collection of the surveillance network was then investigated 
for isolates with a voriconazole MIC of ≥16 mg/L. Since May 2009, when screening 
of isolates using the 4D plates had begun, 5 of 33 azole-resistant isolates were 
identiﬁed with a voriconazole MIC of ≥16 mg/L. Sequence-based analyses of the 
cyp51A gene of these isolates identiﬁed a third isolate, harboring the  TR46/Y121F/
T289A resistance mechanism, that had been cultured on 31 December 2009 in 
Utrecht. This was considered to be the ﬁrst clinical isolate from our surveillance 
network to harbor the TR46/Y121F/T289A resistance mechanism.   
Prevalence of the TR46/Y121F/T289A Resistance Mechanism. From December 
2009 to January 2011, 1315 A. fumigatus isolates from 921 patients were screened 
for resistance in 7 of 8 university centers. In one center, the total number of 
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isolates screened was unknown, as this center did not complete the online 
questionnaire for susceptible isolates. The overall prevalence of azole resistance 
was 6.8% (63 of 921 patients). Forty-seven of 63 patients (74.6%) harbored the 
TR34/L98H resistance mechanism and 13 patients (20.6%) TR46/Y121F/ T289A. No 
cyp51A mutations were found in azole-resistant A. fumigatus isolates from 3 
patients (4.7%). The prevalence of TR46/Y121F/T289A was 1.4% (13 of 921 
patients) in this 14-month period. Besides this, 2 isolates with TR46/Y121F/T289A 
and 2 isolates with TR34/L98H were recovered from the center that had not 
recorded the total number of screened isolates. Therefore, within 14 months 
(December 2009 to January 2011), TR46/Y121F/T289A was detected in 21 clinical 
A. fumigatus isolates obtained from 15 patients in 6 different university hospitals 
in the Netherlands (Table 1, Figure 1).  
Characterization of TR46/Y121F/T289A Isolates. The 21 TR46/Y121F/T289A 
isolates were identiﬁed as A. fumigatus based on sequence analysis of the 
β-tubulin and calmodulin genes, and voriconazole showed no in vitro activity 
against any of the isolates (MIC ≥16 mg/L). The activity of itraconazole and 
posaconazole was attenuated in all isolates (Table 1). The DMI tebuconazole, 
which has been shown to exhibit activity against wild-type A. fumigatus 
isolates,[11] showed no in vitro activity against TR46/Y121F/T289A isolates. One 
isolate with TR46/Y121F/T289A contained 2 additional substitutions, M172I and 
G448S. Recombinant experiments conﬁrmed the association between the TR46/
Y121F/T289A resistance mechanism and the observed phenotype (data not 
shown).  
 Microsatellite genotyping showed that clinical TR46/Y121F/T289A 
isolates clustered together. TR46/Y121F/T289A and TR34/L98H were separated into 
different clades and apart from wild-type control isolates (Figure 2).   
Clinical Characteristics. Among the 15 patients identiﬁed with a TR46/Y121F/
T289A isolate, 8 were diagnosed with azole-resistant invasive aspergillosis (Table 
1). Three of these patients were classiﬁed as having probable disease and 4 as 
proven. One patient could not be classiﬁed according to the EORTC/MSG 
consensus deﬁnitions.[30] This patient showed bone destruction of the skull on 
computed tomography scan and A. fumigatus was recovered repeatedly from 
the ear, without any other explanation. All patients with invasive aspergillosis 
due to TR46/Y121F/T289A were azole-naive, except 1 patient with probable and 1 
patient with proven invasive aspergillosis. At 12 weeks after recovery of the TR46/
Y121F/T289A isolate, 4 of 8 patients with invasive aspergillosis had died and 2 
patients had a persisting infection. All patients who died had received primary 
therapy with voriconazole. In 4 patients, primary therapy was initiated with 
liposomal amphotericin B. In 3 of these patients, invasive aspergillosis was 
diagnosed, and all patients were alive at 12 weeks (Table 1).   
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Environmental Sampling. A total of 140 azole-resistant A. fumigatus colonies 
were identiﬁed, recovered from 21 locations at 9 different sites (outdoor and 
indoor). Aspergillus fumigatus colonies could not be recovered from 3 samples 
(entrance of 1 of the hospitals and 2 domiciles) due to abundant growth of 
zygomycetes. Analysis of the cyp51A gene and the promoter region showed that 
126 (90%) isolates harbored TR34/L98H, and 14 (10%) harbored the new TR46/
Y121F/T289A resistance mechanism. Both resistance mechanisms were found in 
the Nijmegen and Groningen areas (Figure 1). In 6 of 10 sampled sites, the TR46/
Y121F/T289A resistance mechanism was found, and TR34/L98H was recovered 
from 9 of 10 sites (Table 2). The genotypes of 11 of the 14 environmental TR46/
Y121F/T289A grouped together with the clinical TR46/Y121F/T289A isolates, 
irrespective of the geographic site of recovery, whereas susceptible control 
isolates and TR34/L98H isolates generally clustered in different clades (Figure 2).
 
Discussion
We describe the emergence and migration of a new azole resistance mechanism 
in A. fumigatus, a major cause of fungal diseases in humans. The new TR46/Y121F/
T289A resistance mechanism conferred high resistance to voriconazole and was 
associated with treatment failure in patients with invasive aspergillosis. Isolates 
harboring TR46/Y121F/T289A were recovered from the environment, indicating 
that selection through a fungicide-driven route could have taken place. 
 TR34/L98H was the ﬁrst resistance mechanism that has been recovered 
from both clinical specimens and from the environment in the Netherlands. 
This resistance mechanism ﬁrst emerged in clinical A. fumigatus isolates in 
Figure 1. Geographical map of the 
Netherlands indicating screening 
sites and recovery of clinical and 
environmental TR46/Y121F/T289A 
isolates.
Circles indicate hospitals where 
screening of clinical isolates took 
place and squares indicate the sites 
where air sampling took place. Gray 
indicates the presence of TR46/Y121F/
T289A isolates and white the absence 
of TR46/Y121F/T289A.
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1998.[4,6] A Dutch survey performed between 2007 and 2009 showed that 
TR34/L98H was widespread and that the prevalence varied between 0.8% and 
9.5%.[7] TR34/L98H was found in azole-resistant A. fumigatus isolates that were 
recovered from environmental sources, such as soil and compost.[10] A second 
resistance mechanism reported in the Netherlands was a 53 base-pair tandem 
repeat (TR53) without mutations in the cyp51A gene. TR53 was associated with 
a pan-azole-resistant phenotype and was reported to have caused Aspergillus 
osteomyelitis in a pediatric patient in 2006.[31] Although a TR53 isolate 
was recovered from the environment (Verweij and Melchers, unpublished 
observations), there is currently no evidence for migration of this resistance 
mechanism. Our current study describes TR46/Y121F/T289A as the third 
resistance mechanism that has emerged in clinical and environmental isolates. 
 Similar to TR34/L98H,[11] the fungicide-driven route of resistance 
development could have caused the emergence of TR46/Y121F/T289A. Both 
resistance mechanisms consist of a combination of genomic changes that 
include a tandem repeat.[15,32] The new resistance mechanism included 
3 genomic changes, and it appears unlikely that these would have evolved 
during azole therapy in all individual cases. Until now, only point mutations 
have been described to have developed in azole-resistant A. fumigatus 
isolates through patient therapy.[14,27] Both TR34/L98H and TR46/Y121F/
T289A were recovered from epidemiologically unrelated patients, most of 
whom were azole-naive, and both were recovered from the environment. 
Furthermore, genetic typing showed clustering of TR34/L98H and TR46/
Y121F/T289A in separate clades apart from wild-type isolates.   
 The evolving epidemiology of TR34/L98H indicates that this resistance 
mechanism is not restricted to the Netherlands but is increasingly being 
observed in other European Union member states[6,13-19,22,23] and outside 
Europe.[20,21] Genotyping indicates that in Europe, TR34/L98H isolates 
Figure 2. Allele sharing distance 
matrices of the microsatellite genotypes 
of the clinical and environmental 
resistant TR46/Y121F/T289A isolates, 
compared with TR34/L98H and wild-
type controls. Red dots: TR46/Y121F/
T289A isolates from clinical origin; red 
squares: TR46/Y121F/T289A isolates 
from environmental origin; blue dots: 
TR34/L98H isolates; green dots: wild-
type isolates.    
    
77
4
 
78   | Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and   
 recovery of genetically related resistant isolates from domiciles. 
represent offspring of a common ancestor[24] and could have developed 
locally, possibly in the Netherlands, and subsequently spread across countries 
through wind-dispersed conidia or  ascospores. Given the rapid geographical 
migration of TR46/Y121F/T289A in Dutch hospitals, it can be anticipated that 
this resistance mechanism will spread, similar to TR34/L98H. Indeed, recently 
a lethal case of azole-resistant invasive aspergillosis due to TR46/Y121F/
T289A was reported in a patient from the neighboring country of Belgium.[33] 
 Resistance threatens the outcome of patients with Aspergillus-
related diseases, especially those with azole-resistant invasive aspergillosis. 
Voriconazole, which is recommended for the primary therapy of invasive 
aspergillosis, was uniformly inactive against TR46/Y121F/T289A isolates, and 
treatment failed in all patients with proven or probable invasive aspergillosis who 
had received primary therapy with voriconazole. As the activity of itraconazole 
and posaconazole was also reduced in the majority of the isolates, the azole class 
appears not to be a treatment option in patients with infection with A. fumigatus 
harboring TR46/Y121F/T289A.        
 There are limited clinical data regarding alternative treatment options in 
azole-resistant invasive aspergillosis. In vitro and experimental studies indicated 
that the combination of voriconazole and anidulafungin was synergistic 
against azole-susceptible infection but that in voriconazole-resistant disease, 
synergism was lost.[34,35] There is concern that in infection with isolates where 
voriconazole shows no activity, such as the TR46/Y121F/T289A strains, the efﬁcacy 
of the combination will rely solely on that of anidulafungin, which is suboptimal.
[35] In a murine model of disseminated aspergillosis, liposomal amphotericin 
B was shown to be effective against azole-resistant A. fumigatus with various 
resistance mechanisms, including TR46/Y121F/T289A.[36] In our current 
study, patients who received primary therapy with liposomal amphotericin B 
appeared to respond better than those receiving voriconazole, although the 
number of patients was very limited and the underlying conditions diverse. 
 Systematic surveillance through a network of clinical microbiology 
laboratories proved to be a useful strategy to detect the emergence and spread 
of the new resistance mechanism in A. fumigatus. Given the observed spread 
of azole resistance across Europe we believe that international surveillance 
programs are warranted. We believe that our observations are very worrisome 
as they indicate that continued use of triazole DMIs in our environment with 
activity against A. fumigatus will not only help resistance traits to sustain in the 
environment, but will also cause new resistance mechanisms to emerge. The 
potential of geographical migration, as observed with TR34/L98H, indicates that 
the fungicide-driven route of resistance selection will not remain a regional 
problem. Unless we are able to implement measures that prevent fungicide-
driven resistance selection, the clinical use of azoles will become severely 
compromised. It is therefore important to understand the conditions that allow 
for selection of resistance in the environment and to investigate which preventive 
measures might be effective.
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Drawing made by a 16-year old girl suffering from acute lymphoblastic leukemia and 
pulmonary and cutaneous azole-resistant invasive aspergillosis. 
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Abstract  
Azole resistance has emerged in Aspergillus fumigatus but the frequency of 
resistance is unknown in many countries. Therefore, for one year 3,788 clinical 
Aspergillus isolates were screened for resistance at 22 centres in 19 countries. 
The overall prevalence of azole resistance in patients with A. fumigatus species 
complex (sc) isolates was 3.2% and ranged from 0 to 26.1% per centre. Sixty 
azole-resistant A. fumigatus sc isolates were recovered from 46 patients from 11 
countries. Forty-seven of 60 azole-resistant isolates were classified as A. 
fumigatus by molecular identification and 13 as A. fumigatus sibling species: A. 
lentulus and Neosartorya species. TR34/L98H was the most frequent azole 
resistance mechanism, and was found in isolates originating from Austria, 
Belgium, Denmark, France, Italy and the Netherlands. Of 46 patients with an 
azole-resistant isolate 28 had documented Aspergillus disease and azole 
resistance was found in 10 of 195 patients with invasive aspergillosis (5.1%). 
 
Introduction  
Aspergillus fumigatus is a saprofytic mould that finds its ecological niche in 
decaying organic matter.[1] Conidia of A. fumigatus are widely dispersed in the 
air and after inhalation by a susceptible host Aspergillus is able to cause a wide 
spectrum of diseases, varying from chronic localized to acute invasive disease.
[2] Invasive aspergillosis (IA) occurs mainly in severely immunocompromised 
patients and may be associated with high mortality rates.[3,4] The most 
important class of antifungal drugs with activity against aspergilli are the 
triazoles including the clinically licensed drugs itraconazole, posaconazole and 
voriconazole. Voriconazole is the recommended first choice compound for 
treatment of IA.[4,5]  
 Reports indicate that azole resistance in A. fumigatus is an emerging 
clinical problem.[6,7] New sibling species of A. fumigatus have been reported to 
cause IA, and are generally less susceptible to azole compounds compared to A. 
fumigatus.[8-10]   
 Acquired azole resistance has been found mainly in A. fumigatus 
following chronic azole therapy.[11-14] In azole-treated patients with 
aspergilloma multiple resistance mechanisms were found in individual A. 
fumigatus colonies, indicating that in this specific setting the fungus is capable 
of rapidly adapting to azole exposure.[14]      
 An alternative route of resistance selection appears through 
environmental exposure of A. fumigatus to azole fungicides. It is suggested that 
in A. fumigatus resistance mechanisms are selected in the environment, and that 
these mechanisms reduce the efficacy of the medical triazoles because of 
similarities between the molecular structure of azole fungicides and the medical 
triazoles.[15-19] Unlike the patient route, the fungicide-driven route of resistance 
selection carries the risk of geographical migration. In the Netherlands, the 
resistance mechanism from environmental origin, a combination of mutations 
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in the cyp51A gene (TR34/L98H) is highly dominant, contributing to over 90% of 
resistance mechanisms found in azole-resistant isolates.[6,20] Azole resistance 
has been observed in patients with no recent history of azole therapy and the 
mortality in patients with azole-resistant IA was 88%.[20]  
 As in vitro susceptibility testing of Aspergilli is currently not routinely 
performed in most clinical microbiology laboratories, the global prevalence of 
azole resistance is not well characterized. The aim of our study was to investigate 
the prevalence of azole resistance in clinical Aspergillus isolates. A multicenter 
international surveillance network was set up in 2009 (Surveillance Collaboration 
on Aspergillus Resistance in Europe, SCARE-network). This network involved 18 
European and 4 non-European sites.  
 
Materials and methods  
Surveillance network. A multicentre international surveillance network was 
established, including 22 centres from 19 countries: Melbourne (Australia), 
Innsbruck (Austria), Leuven (Belgium), Rio de Janeiro and Porto Alegre (Brazil), 
Copenhagen (Denmark), Paris and Grenoble (France), Munster (Germany), 
London and Manchester (Great-Britain), Athens (Greece), Milan (Italy), Nijmegen 
(the Netherlands), Oslo (Norway), Gdansk (Poland), St Petersburg (Russia), 
Madrid (Spain), Stockholm (Sweden), Lausanne (Switzerland), Ankara (Turkey) 
and Birmingham (USA). The centres were asked to screen for azole resistance for 
a period of 12 consecutive months.                   
Screening method. To detect azole-resistant A. fumigatus a phenotypic 
screening-method was developed using a four-well plate format. Three of the 
four wells contained RPMI-1640 supplemented with itraconazole (4 mg/l), 
voriconazole (1 mg/l) and posaconazole (0.5 mg/l), respectively. The fourth well 
contained RPMI-1640 with no azole supplement and served as growth control.
[21] All clinical Aspergillus isolates that were found in primary culture were 
subcultured on the four-well azole-agar plate, irrespective of its clinical 
significance, with a maximum of up to four colonies per clinical sample.  For 
each screened isolate, patient characteristics were registered via an online 
questionnaire including age, gender, underlying disease, risk factors for invasive 
fungal disease (haematopoietic stem cell transplantation, corticosteroid use 
and intensive care unit admission), antifungal use in the three months prior to 
culture and presence of Aspergillus disease. Patients with IA were classified 
according to the EORTC/MSG consensus definitions, using radiologic imaging 
and microbiological results.[22] Two centres were reference laboratories with no 
access to clinical data. Human experimentation guidelines from the Committee 
on Research Involving Human Subjects Arnhem–Nijmegen were followed in the 
conduct of this research.   
 The four-well azole-agar dilution plates were prepared at the Radboud 
University Medical Centre Nijmegen, Department of Medical Microbiology, the 
Netherlands, and distributed to the other centres for proficiency testing. Each 
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centre was provided with a protocol and a blinded set of five A. fumigatus 
isolates. Two were multi azole-resistant (MICs: itraconazole >16 mg/l, 
voriconazole 4 and 8 mg/l, and posaconazole 0.5 mg/l), and three were 
susceptible. The centres were blinded for the resistance profiles and were asked 
to determine the ability of the isolates to grow on the four-well azole-agar 
dilution plates.  
Phenotypic and genotypic analyses. Species identification was performed by 
macroscopic and microscopic morphology at the participating centres. Azole-
agar dilution plates were incubated at 37ºC and growth was assessed after 48 
hours. For every A. fumigatus isolate that was able to grow on any of the azole-
containing wells, the primary culture isolate was sent to the Radboud University 
Medical Centre Nijmegen, the Netherlands and Statens Serum Institute, Denmark 
for susceptibility testing according to the EUCAST broth microdilution reference 
method.[23] The in vitro activities of itraconazole, voriconazole, posaconazole, 
and the azole fungicide tebuconazole were determined.   
 For every isolate that was classified as azole-resistant molecular species 
identification and mutation analysis were performed. Molecular species 
identification was performed by sequencing parts of the β-tubulin gene, as 
described previously.[8,9] If molecular identification classified the isolate as A. 
fumigatus, the full coding sequence of both strands of the cyp51A gene were 
determined by PCR amplification. PCR products were separated on an agarose 
gel, purified, sequenced, and aligned to the reference bank (GenBank AF338659) 
to detect any mutations, as described previously.[24]  
 For every confirmed resistant isolate one susceptible isolate was 
assigned, as being the first susceptible isolate recovered after the resistant 
isolate. Susceptibility testing and molecular identification were also performed 
on the susceptible isolates, as described above.  
Statistical analyses. χ2 tests and ANOVA were performed by using SPSS version 
20.0 (IBM, Somers, NY, USA).  
 
Results  
Proficiency testing. Nineteen of the 22 centres completed the proficiency 
testing. All centres correctly identified the two resistant isolates using the azole-
agar dilution plates. Six centres incorrectly assessed a susceptible isolate as 
being resistant due to growth in the azole-agar after 48 hours of incubation. This 
was the case for one susceptible isolate in 1/22 centres, two susceptible isolates 
in 4/22 centres and all three susceptible isolates in 1/22 centres. Sensitivity of 
the azole-agar dilution plates for detection of resistance was therefore calculated 
to be 100%, with no false-negative results, but with an estimated rate of 21% 
false-positive results to arise from this study design (12/57 tests of susceptible 
isolates).   
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Participation in screening for resistance. A total of 3,788 Aspergillus isolates 
were screened for the presence of azole resistance by use of the four-well plates 
between January 2009 and January 2011. All centres screened for one year, 
except for one centre which screened for a 8-month period. The number of 
isolates screened per centre varied between 16 and 587, with a median of 82 
(Figure 1).   
 Patient information was available from 1,911 patients from 21 centres 
from 18 countries. In one centre 264 isolates were screened, but patient 
information was not collected due to the fact that this was a mycology reference 
Figure 1. Study characteristics (number of isolates/patients screened) from 22 centers in 
19 countries participating in a study of azole resistance in Aspergillus fumigatus. *Period 
screened was 8 months instead of 1 year in this center for unknown reason. †Total 
number of screened patients is unknown because this center is a reference laboratory 
that does not have access to patient characteristics.
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laboratory. Patient age ranged from 0 to 97 years (mean: 49.8 years) and 55% of 
patients were males. The number of Aspergillus isolates screened per patient 
ranged from 1 to 17 (median 1).  
Isolate characteristics. The majority of isolates (2,941 of 3,788, 77.6%) were 
classified as A. fumigatus species complex (sc). Among the remaining 847 
isolates, A. flavus and A. niger sc were most frequent (Table 1). Most specimens 
(81.6%) were respiratory specimens, including sputum, tracheo-broncheal 
aspirates or bronchoalveolar lavage fluid (39.1%, 29.5% and 13%, respectively). 
Only a minority of isolates (2.2%) were recovered from other body sites including 
pleural fluid, pus, ascites, peritoneal fluid, blood, urine and cerebrospinal fluid. 
Tissue samples from normally sterile sites were responsible for 3.4% of the 
isolates and were obtained from biopsies and at autopsy (Table 1). Forty-five per 
cent of positive cultures from ear-swabs were A. niger species complex isolates. 
Patient characteristics for patients with A. fumigatus sc isolates. A. fumigatus 
sc isolates were recovered from 1,450 patients. The most common underlying 
disease was chronic lung disease (30.0%), followed by cystic fibrosis (22.1%) and 
haemato-oncological diseases (12.9%)(Table 1). A total of 204 patients (14.1%) 
had undergone haematopoietic stem cell transplantation or solid organ 
transplantation and 265 patients (18.3%) had been treated with corticosteroids 
within three months prior to culture of the isolate. Two hundred and twenty 
three of 1,450 patients (15.4%) had received antifungals within three months 
prior to, or at the time of the positive culture. The majority (132/223, 59.2%) of 
these received azole monotherapy, including itraconazole, voriconazole or 
posaconazole, and 22 (9.9%) received combination therapy with an azole and a 
polyene or an echinocandin. The remaining patients were previously treated 
with fluconazole (32 patients), a polyene (16 patients) or an echinocandin (11 
patients). Five patients received combination-therapy of a polyene drug together 
with an echinocandin. Finally, in five patients the antifungal treatment regimen 
was not specified.   
 For 806 patients (55.6%) the clinical relevance of the cultured A. fumigatus 
species complex isolate was reported and in 453 patients there was no evidence 
for Aspergillus disease. In 353 patients Aspergillus disease was diagnosed. In the 
group of patients in whom the relevance of the Aspergillus isolate was reported 
(806 patients) 23.3% (n=188) were diagnosed with possible (36 patients), 
probable (108 patients) or proven IA (44 patients) and 19.6% (n=158) were 
diagnosed with non-invasive Aspergillus disease. In 24 patients the infection was 
not classified. In the group of 158 patients with non-invasive disease most had 
aspergilloma (50 patients) or allergic bronchopulmonary aspergillosis (ABPA, 46 
patients). Twenty-four patients were diagnosed with other forms of non-invasive 
disease, being chronic pulmonary aspergillosis and bronchitis, this entity was 
not further specified due to logical reasons on the online questionare. One 
patient suffered from a combination of ABPA with chronic pulmonary aspergillosis 
(Figure 2).  
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Analysis of azole-resistant A. fumigatus sc isolates. One-hundred eighty-one 
A. fumigatus sc isolates were able to grow on at least one of the azole-containing 
agar-wells and were tested according to the EUCAST broth microdilution 
reference method.[23] For 60 of 181 isolates (32.1%) the resistant phenotype 
was confirmed in vitro (Table 2), therefore the number of false-positive results 
on the azole-containing agar-plates was 121 of 2,941 isolates (4.1%). The 60 
azole-resistant isolates were matched with 60 control isolates from each site 
which were unable to grow on the azole-containing wells of the screening plate. 
The in vitro susceptibility of these isolates is shown in Table 2.     
  
Table 1. Isolate characteristics of 3,788 screened Aspergillus isolates from 1,911 patients 
and underlying diseases in patients with A. section Fumigati (1,450).  
No. %
Species
A. section Fumigati 2,941 77.6
A. section Nigri 315 8.3
A. section Flavi 211 5.6
A. section Terrei 105 2.8
A. section Nidulanti 53 1.4
Other Aspergillus species 163 4.3
Specimen
Sputum 1,482 39.1
Bronchial secretion/ tracheal aspirate 1,116 29.5
Bronchoalveolar lavage fluid 494 13.0
Ear swab 261 6.9
Non-sterile (skin, nail, hair, faeces, mouth-wash) 155 4.1
Specimen from normally sterile tissue 129 3.4
Specimen from normally sterile fluid 83 2.2
Nasal/sinus swab 36 0.9
Unknown/other 32 0.8
Underlying diseases in 1,450 patients with A. section Fumigati isolates
Chronic lung disease (excl. cystic fibrosis) 435 30.0
Cystic fibrosis 320 22.1
General internal disease (incl. auto-immune 
disease, AIDS, chronic granulomatous disease) 157 10.8
93
5
 Sequencing of the β-tubulin-gene classified 47 azole-resistant isolates 
(78.3%) as A. fumigatus. The other 13 azole-resistant isolates were classified as A. 
lentulus (n=7), Neosartorya pseudofisheri (n=4) and N. udagawae (n=2). In the 
control-group all 60 isolates were classified as A. fumigatus.    
 Sequence analysis of the cyp51A gene of A. fumigatus showed the 
presence of TR34/L98H in 23 of the azole-resistant A. fumigatus isolates (48.9%). 
All TR34/L98H isolates were cultured from patients from European centres 
(Vienna, Leuven, Copenhagen, Paris, Milan and Nijmegen). In three isolates from 
the Netherlands a new resistance mechanism was found, which consisted of a 46 
base-pair tandem repeat in the promoter region combined with two substitutions 
in the cyp51A gene (TR46/Y121F/T289A).[25] Although a significant proportion of 
azole-resistant isolates (13 of 47, 27.7%) were recovered from patients from the 
UK, none of them harboured the TR34/L98H resistance mechanism. Overall, in 14 
isolates other mutations were found in the cyp51A gene. Nine isolates had 
substitutions in recognised hotspots at codon M220 and four at codon G54. One 
isolate from the UK contained a point mutation (L329V) not reported to be 
associated with azole resistance.[12] In four isolates a series of mutations was 
Figure 2. Patient characteristics and underlying resistance mechanisms of patients 
with invasive and noninvasive Aspergillus disease. *Otomycosis, dermatomycosis, or 
onychomycosis; 1 patient had a resistant isolate and otomycosis. †One patient had 
chronic pulmonary aspergillosis and ABPA. ‡Not classified according to European 
Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria 
(5). §One patient is included with 46-bp tandem-repeat resistance mechanism. ABPA, 
allergic bronchopulmonary aspergillosis; CPA, chronic pulmonary aspergillosis; 
R, resistant; S, susceptible; –, negative; +, positive.
94   |   Prospective multicentre international surveillance of azole resistance   
 in Aspergillus fumigatus (SCARE-network). 
found. In seven azole-resistant A. fumigatus isolates no mutations were found in 
the cyp51A-gene, indicating the presence of another, yet unknown, resistance 
mechanism (Table 3).  
 The in vitro susceptibility of the azole-resistant A. fumigatus (47 isolates), 
the A. fumigatus sibling species (13 isolates) and the control isolates (60 isolates) 
is shown in Table 2. All control isolates were susceptible to itraconazole, 
voriconazole and posaconazole. The in vitro activity of the azole fungicide 
tebuconazole is also shown in Table 2. The medical triazoles were less active 
against the A. fumigatus sibling group compared to A. fumigatus. However, the A. 
fumigatus sibling group was significantly more susceptible to itraconazole and 
posaconazole, when compared to the azole-resistant A. fumigatus isolates 
(p<0.05)(Table 2). The azole fungicide tebuconazole was in general more active, 
although the difference was not statistically significant, against the azole-
resistant A. fumigatus group compared with the sibling species (p=0.09)(Table 
2).      
Prevalence of azole resistance. In total, 60 azole-resistant isolates were 
recovered from 46 patients. Six isolates were from the reference laboratories 
without access to clinical details. The overall prevalence of azole resistance 
amongst patients with A. fumigatus sc isolates was 3.2%, which ranged from 
0.0% to 26.1% between the centres. Azole resistance was detected in 11 of 19 
(57.9%) participating countries. Azole resistance was not found in the centres 
from Brazil, Greece, Norway, Poland, Russia, Switzerland, Turkey and the USA. 
The probability of detecting resistance corresponded with the number of isolates 
that were screened per centre. In 88.9% of the centres where no resistance was 
detected less than 50 isolates per centre were screened within the 12 month 
period. This contrasted with the centres where azole resistance was observed, as 
in only 7.7% of these centres less than 50 isolates per centre had been screened 
(p<0.01).   
Median MIC, mg/L
Isolate Itraconazole Voriconazole Posaconazole Tebuconazole
Azole-resistant 
Aspergillus fumigatus, 
n = 47
>8 2 1 8
A. fumigatus sibling 
species,* n = 13
1 2 0.25 >8
A. fumigatus controls, 
n = 60
0.25 0.5 0.06 2
  *Aspergillus lentulus, Neosartorya pseudofischeri, N. udagawae. 
Table 2. Susceptibility for 3 antifungal medical azoles and 1 azole fungicide of resistant 
isolates (60 isolates) and control group (60 isolates) after species identification. 
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Table 4. Clinical characteristics of 28 patients with documented azole-resistant Aspergillus diseases.* 
Patient 
no.
Sex/ 
age
Country Underlying condition Cortico- 
steroid 
use
Date/specimen Species Resistance mechanism Aspergillus disease Previous 
treatment
Out- come
1 F/29 Denmark cystic fibrosis no 2009 May, sputum A. fumigatus (2) TR34/L98H ABPA VCZ survived
2 M/75 Italy pulmonary disease no 2009 May, sputum A. fumigatus TR34/L98H Possible IA none survived
3 M/66 Netherlands hematologic disease yes 2009 May, sputum A. fumigatus TR34/L98H Possible IA none died
4 F/61 UK pulmonary disease yes 2009 May, sputum A. fumigatus M220K, E317G CPA/ABPA AMB died
5 M/55 UK oncologic disease no 2009 May, sputum A. fumigatus L329V CPA ITZ died
6 F/18 UK cystic fibrosis no 2009 May, sputum A. fumigatus P381R, D481E Bilateral aspergilloma VCZ died
7 F/62 Netherlands hematologic malignancy, HSCT yes 2009 Aug, mouth  
wash
A. fumigatus TR34/L98H Possible IA none survived
8 M/61 Netherlands hematologic malignancy, HSCT yes 2009 Aug, sputum A. fumigatus TR34/L98H Possible IA none died
9 F/30 Austria Otomycosis no 2009 Sep, ear swab  
sample
A. fumigatus (2) TR34/L98H Otomycosis none survived
10 M/60 Netherlands hematologic malignancy, HSCT yes 2009 Sep, sputum A. fumigatus TR34/L98H Possible IA none survived
11 F/50 UK pulmonary disease no 2009 Sep, sputum A. fumigatus L77V, L399I, D481E CPA VCZ ongoing infection
12 M/16 Denmark cystic fibrosis no 2009 Oct, sputum A. fumigatus no Cyp51A mutation ABPA VCZ survived
13 M/71 UK pulmonary disease no 2009 Oct, sputum A. fumigatus M220I, L319V CPA POS died
14 M/57 UK pulmonary disease no 2009 Oct, sputum A. fumigatus no Cyp51A mutation CPA AMB ongoing infection
15 F/56 UK pulmonary disease no 2009 Nov, sputum A. fumigatus G54R CPA POS ongoing infection
16 M/80 UK pulmonary disease no 2009 Nov, sputum A. fumigatus M220R CPA ITZ died
17 M/19 France cystic fibrosis no 2009 Dec, sputum A. fumigatus no Cyp51A mutation Bronchitis VCZ ongoing infection
18 F/59 UK pulmonary disease no 2009 Dec, sputum A. fumigatus no Cyp51A mutation Aspergilloma VCZ died
19 M/75 Belgium pulmonary disease yes 2010 Jan, BAL A. fumigatus TR34/L98H Probable IA none died
20 F/51 Netherlands kidney transplant yes 2010 Jan, kidney  
biopsy sample
A. fumigatus (3) TR46/Y121F/T289A Proven IA none died
21 M/67 UK pulmonary disease no 2010 Jan, sputum A. fumigatus G54E CPA POS ongoing infection
22 M/54 Denmark cystic fibrosis, lung transplant no 2010 Jan, BAL A. fumigatus (2) TR34/L98H Possible IA VCZ  died
23 M/62 Belgium pulmonary disease, lung transplant yes 2010 Feb, lung  
biopsy sample
A. fumigatus TR34/L98H Proven IA VCZ, POS died
24 F/26 Australia cystic fibrosis yes 2010 Feb, sputum N. pseudofischeri unknown ABPA VCZ survived
25 M/78 UK pulmonary disease no 2010 Mar, sputum A. fumigatus G54W, Q249H CPA POS died
26 M/41 UK cystic fibrosis yes 2010 Mar, sputum N. pseudofischeri unknown ABPA AMB ongoing infection
27 M/53 Denmark pulmonary disease no 2010 Apr, sputum A. fumigatus no Cyp51A mutation Aspergilloma ITZ survived
28 M/71 UK pulmonary disease no 2010 May, sputum A. fumigatus M220I Proven IA AMB, VCZ, 
POS
died
*ABPA, allergic bronchopulmonary aspergillosis; IA, invasive aspergillosis; AMB, amphotericin B; BAL,                                   
bronchoalveolar lavage fluid; CPA, chronic pulmonary aspergillosis; HSCT, hematopoietic stem cell  
transplantation; ITZ, itraconazole; POS, posaconazole; VCZ, voriconazole.
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Sex/ 
age
Country Underlying condition Cortico- 
steroid 
use
Date/specimen Species Resistance mechanism Aspergillus disease Previous 
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Out- come
1 F/29 Denmark cystic fibrosis no 2009 May, sputum A. fumigatus (2) TR34/L98H ABPA VCZ survived
2 M/75 Italy pulmonary disease no 2009 May, sputum A. fumigatus TR34/L98H Possible IA none survived
3 M/66 Netherlands hematologic disease yes 2009 May, sputum A. fumigatus TR34/L98H Possible IA none died
4 F/61 UK pulmonary disease yes 2009 May, sputum A. fumigatus M220K, E317G CPA/ABPA AMB died
5 M/55 UK oncologic disease no 2009 May, sputum A. fumigatus L329V CPA ITZ died
6 F/18 UK cystic fibrosis no 2009 May, sputum A. fumigatus P381R, D481E Bilateral aspergilloma VCZ died
7 F/62 Netherlands hematologic malignancy, HSCT yes 2009 Aug, mouth  
wash
A. fumigatus TR34/L98H Possible IA none survived
8 M/61 Netherlands hematologic malignancy, HSCT yes 2009 Aug, sputum A. fumigatus TR34/L98H Possible IA none died
9 F/30 Austria Otomycosis no 2009 Sep, ear swab  
sample
A. fumigatus (2) TR34/L98H Otomycosis none survived
10 M/60 Netherlands hematologic malignancy, HSCT yes 2009 Sep, sputum A. fumigatus TR34/L98H Possible IA none survived
11 F/50 UK pulmonary disease no 2009 Sep, sputum A. fumigatus L77V, L399I, D481E CPA VCZ ongoing infection
12 M/16 Denmark cystic fibrosis no 2009 Oct, sputum A. fumigatus no Cyp51A mutation ABPA VCZ survived
13 M/71 UK pulmonary disease no 2009 Oct, sputum A. fumigatus M220I, L319V CPA POS died
14 M/57 UK pulmonary disease no 2009 Oct, sputum A. fumigatus no Cyp51A mutation CPA AMB ongoing infection
15 F/56 UK pulmonary disease no 2009 Nov, sputum A. fumigatus G54R CPA POS ongoing infection
16 M/80 UK pulmonary disease no 2009 Nov, sputum A. fumigatus M220R CPA ITZ died
17 M/19 France cystic fibrosis no 2009 Dec, sputum A. fumigatus no Cyp51A mutation Bronchitis VCZ ongoing infection
18 F/59 UK pulmonary disease no 2009 Dec, sputum A. fumigatus no Cyp51A mutation Aspergilloma VCZ died
19 M/75 Belgium pulmonary disease yes 2010 Jan, BAL A. fumigatus TR34/L98H Probable IA none died
20 F/51 Netherlands kidney transplant yes 2010 Jan, kidney  
biopsy sample
A. fumigatus (3) TR46/Y121F/T289A Proven IA none died
21 M/67 UK pulmonary disease no 2010 Jan, sputum A. fumigatus G54E CPA POS ongoing infection
22 M/54 Denmark cystic fibrosis, lung transplant no 2010 Jan, BAL A. fumigatus (2) TR34/L98H Possible IA VCZ  died
23 M/62 Belgium pulmonary disease, lung transplant yes 2010 Feb, lung  
biopsy sample
A. fumigatus TR34/L98H Proven IA VCZ, POS died
24 F/26 Australia cystic fibrosis yes 2010 Feb, sputum N. pseudofischeri unknown ABPA VCZ survived
25 M/78 UK pulmonary disease no 2010 Mar, sputum A. fumigatus G54W, Q249H CPA POS died
26 M/41 UK cystic fibrosis yes 2010 Mar, sputum N. pseudofischeri unknown ABPA AMB ongoing infection
27 M/53 Denmark pulmonary disease no 2010 Apr, sputum A. fumigatus no Cyp51A mutation Aspergilloma ITZ survived
28 M/71 UK pulmonary disease no 2010 May, sputum A. fumigatus M220I Proven IA AMB, VCZ, 
POS
died
*ABPA, allergic bronchopulmonary aspergillosis; IA, invasive aspergillosis; AMB, amphotericin B; BAL,                                   
bronchoalveolar lavage fluid; CPA, chronic pulmonary aspergillosis; HSCT, hematopoietic stem cell  
transplantation; ITZ, itraconazole; POS, posaconazole; VCZ, voriconazole.
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 Acquired resistance in A. fumigatus was found at 11 (50.0%) of the 
participating centres, which were all European: Austria, Belgium, Denmark, 
France, Italy, the Netherlands, Spain, Sweden and United Kingdom. Almost half 
(48.9%) of the azole-resistant isolates from these European countries harboured 
the TR34/L98H resistance mechanism. The prevalence of resistance at the centres 
where TR34/L98H was found, ranged from 2.1% to 6.0%. The highest prevalence 
of azole resistance was seen in patients from Manchester and London, United 
Kingdom (26.1% and 18.2%) and Nijmegen, the Netherlands (6.0%). Manchester 
serves as the National Aspergillosis Centre and many patients with complex 
chronic Aspergillus diseases are referred to this centre.  
 In five countries (Australia, Germany, Spain, Sweden and United 
Kingdom) azole-resistant A. fumigatus sibling species were recovered. In three of 
these countries acquired resistance in A. fumigatus was also found. In Australia 
the prevalence of intrinsic resistance was the highest (5.1%), whereas acquired 
resistance was not found.  
Characteristics of patients harbouring azole-resistant isolates. From the 46 
patients with resistant isolates, the majority suffered from chronic lung disease 
(20/46), cystic fibrosis (14/46) or haemato-oncologic disease (6/46). The 
underlying conditions in the remaining six patients were general internal disease, 
otomycosis, heart-transplantation, kidney-transplantation and post-surgery 
intensive care stay, respectively (Table 4). Fourteen patients had been previously 
treated with corticosteroids and ten were HSCT or SOT recipients. Twenty-three 
patients (50%) had been previously treated with antifungals.   
 Eight patients had azole-resistant A. fumigatus sibling isolates, whilst 38 
had a resistant A. fumigatus isolate. Of these 38 patients, 19 had an isolate which 
harboured a fungicide-driven resistance mechanism, i.e. TR34/L98H or TR46/
Y121F/T289A. When comparing patients with isolates harbouring presumed 
fungicide-driven resistance mechanisms with “non-fungicide driven” resistance 
mechanisms, i.e. point mutations or non-Cyp51A-mediated mechanisms, there 
was a significant difference in azole exposure: 4 of 19 patients (21.1%) with an 
isolate with the fungicide-driven resistance mechanism had a history of azole 
therapy, compared to 16 of 19 patients (84.2%) with isolates with other or no 
cyp51A mutations (p = 0.001)(Figure 2).  
 Of the 195 cases with IA, azole resistance was documented in ten (5.1%)
(three proven, one probable and six possible infections). Amongst the patients 
with resistant isolates there were 28 patients with documented Aspergillus 
disease. Eight patients with a resistant isolate suffered from chronic pulmonary 
aspergillosis, three patients had aspergilloma, four patients were diagnosed 
with ABPA, one patient had chronic Aspergillus bronchitis, and one patient had 
otomycosis. One patient was diagnosed with chronic pulmonary aspergillosis 
but was also treated for ABPA. Eighteen of 46 patients (39.1%) did not have signs 
or symptoms suggesting invasive or non-invasive disease (Table 4). Case-fatality 
rate in our patient cohort with invasive Aspergillus disease was 70%.  
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Discussion  
Our culture-based surveillance study showed that azole resistance is emerging 
among clinical A. fumigatus sc isolates. This substantiates our concern that azole 
resistance is an emerging problem in A. fumigatus. Studies in the United Kingdom 
and the Netherlands described the emergence of azole resistance since 1998.
[6,7,20] Resistance has been sporadically reported over recent years in Austria, 
Belgium, China, Denmark, Germany, France, India, Sweden, Spain and USA.
[13,26-35] In this study, however, acquired resistance was detected in 11 of 17 
European centres in 9 different countries, resulting in an overall prevalence of 
azole resistance of 3.2%, with TR34/L98H being the predominant mechanism of 
resistance (48.9%). Noticeably, 37% of the global market of antifungal pesticides 
is spent in Europe.[19]  
 Previously TR34/L98H was found to be highly dominant in the Netherlands 
and this resistance mechanism is believed to be selected in the environment. 
Molecular typing evidence is accumulating that the TR34/L98H resistance alleles 
are clustered within a single lineage of Dutch populations of A. fumigatus. 
Furthermore, TR34/L98H isolates recovered from other European countries also 
clustered with the Dutch clonal population.[36] The clonal emergence of TR34/
L98H suggests a common ancestor. As the earliest isolates harbouring TR34/L98H 
were recovered in the Netherlands, this might imply that this mechanism 
originated in this country. However, TR34/L98H has now also been reported in 
Asia and the Middle East.[28,29,37] Further studies are needed to help understand 
the origin and geographical migration of azole resistance in the environment. On 
the other hand, resistance in A. fumigatus may have remained undetected in 
other areas as in vitro susceptibility testing was not routinely performed. We 
believe that our study may even have underestimated the true prevalence of 
resistance as centres that screened less than 50 isolates failed to find resistance. 
Furthermore, a recent study suggested an underestimation of the prevalence of 
resistance, as detection of resistance by nucleic acid amplification techniques in 
respiratory samples from patients with chronic lung diseases showed azole 
resistance mechanisms in 55.1% of respiratory specimens.[38]  
 The TR34/L98H was found to be the most predominant resistance 
mechanism, albeit less frequent than previously reported in the Netherlands. 
This could be due to the mix of cases and the possible lower burden of TR34/L98H 
in the environment in other countries. Furthermore, in contrast to other azole 
resistance mechanisms, TR34/L98H was observed more often in patients without 
previous exposure to azoles. There was a predilection of isolates which harboured 
the TR34/L98H mutation for patients with acute invasive diseases when compared 
to patients with aspergilloma and chronic pulmonary aspergillosis. These 
observations support the environmental route of selection of TR34/L98H. 
[6,13,14,18]   
 Through this surveillance network the new resistance mechanism TR46/
Y121F/T289A was found in Dutch A. fumigatus isolates. TR46/Y121F/T289A has 
been found previously in clinical and environmental isolates originating from 
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the Netherlands, and is associated with high level resistance to voriconazole. 
TR46/Y121F/T289A was found to comprise a new clonal population, different 
from TR34/L98H, that has the propensity for rapid geographical migration.[25] 
Indeed, TR46/Y121F/T289A has also been recently recovered in a fatal case of IA in 
Belgium, and most recently from the environment.[39,40] Although speculative, 
it is tempting to anticipate that unless the underlying mechanisms for resistance 
selection in the environment are better understood and appropriate measures 
for prevention of dissemination are implemented, new populations of azole-
resistant A. fumigatus will continue to emerge and migrate, thereby further 
compromising the use of the clinically-licensed azoles in human medicine.  
 Azole-resistant IA was documented in 5.1% of cases of IA, which is not 
lower than the percentage of the prevalence of azole resistance among the A. 
fumigatus isolates (3.2%). This may indicate that resistance does not come with 
a significant fitness cost, and that azole resistant isolates are at least just as 
capable of causing IA as non-resistant wild type isolates. Preclinical studies have 
shown that isolates with a cyp51A-mediated resistance mechanism (including 
the TR34/L98H), exhibit similar virulence when compared to wild type isolates.
[11] For isolates harbouring a fungicide-driven resistance mechanism any fitness 
cost would threaten its survival in the environment in competition with wild type 
isolates. The persistence and geographical migration of TR34/L98H and TR46/
Y121F/T289A also suggests that these resistant strains are not less fit than wild 
types.   
 Although the clinical implications of sibling species of A. fumigatus are at 
present less well understood, our study confirms that these species are generally 
less susceptible to azole antifungal drugs than A. fumigatus.    
 Our study shows that azole resistance is widespread in Europe and 
causes Aspergillus diseases in our patients. Centres that care for patients with 
Aspergillus diseases should perform surveillance in order to determine their 
local epidemiology and perform MIC testing of clinically relevant A. fumigatus 
isolates. Furthermore, azole resistance has become a public health problem 
which needs continued surveillance at the international level and research on 
the mechanisms that enable its selection in the environment.  
 
Conclusion and perspective  
This report of the emergence of resistance on a global scale has launched a new 
phase in the management of Aspergillus diseases. A rapid and convenient 
screening method for resistance is indispensable, because of the rising frequency 
of azole resistance in Aspergillus isolates worldwide and its association with a 
worsened clinical outcome. The global migration of TR34/L98H and TR46/Y121F/
T289A indicates that fungicide-driven resistance mechanisms are not a regional 
problem. Unless we are able to implement measures that prevent the fungicide-
driven route of resistance development, the clinical use of azoles will be severely 
compromised.   
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Our surveillance studies show that azole resistance in A. fumigatus is widespread. 
Coming from a practice that azole resistance was not routinely investigated in 
clinical microbiology laboratories, the presence and frequency of azole resistance 
is clearly underreported. Presently, institutions are starting to investigate azole 
resistance in clinical isolates and stored culture collections, and their result do 
confirm the widespread presence of azole resistance in A. fumigatus. In addition 
to Europe, azole resistance has been reported in the Middle East, Asia, Australia 
and most recently North and South America.[1-23] The anticipated potential 
of global migration has become a reality. Continued surveillance is essential to 
determine resistance frequencies at local, national and international level in 
order to determine trends in resistance frequency, distribution of mutations and 
possibly the emergence of new mechanisms. This is well illustrated in chapter 
4 where the emergence of the TR46/Y121F/T289A resistance mechanism was 
efficiently tracked through the existing surveillance network. This mutation 
is now also found globally and there is recent evidence that TR92 and TR128 
resistance mechanisms have also emerged.[14-23, W.J.G. Melchers, personal 
communication] There are however limitations associated with current 
surveillance studies as they are based on screening for azole resistance of A. 
fumigatus isolated grown from clinical samples. It is well documented that 
Aspergillus culture has a low sensitivity and a recent audit in our hospital indicated 
that only 35% of BAL-cultures were positive in patients with hematological 
malignancy and persistent febrile neutropenia who underwent bronchoalveolar 
lavage as part of a diagnostic work-up for pulmonary infection (P.E. Verweij, 
unpublished data). As a consequence culture-based surveillance studies only 
reflect a minority of the patients with Aspergillus disease. Non-culture based 
assays such as PCR could be used to detect azole resistance mutations directly 
in clinical specimens. This has been shown to be feasible using in-house PCR.
[24] Recently a commercial PCR became available (AsperGenius, PathoNostocs, 
Maastricht), which enabled the detection of two frequent mutations (TR34/L98H 
and  TR46/Y121F/T289A).[25] Initial studies indicate that this allows detection 
of the mutations in culture-negative BAL samples. In a study from Denning 
and colleagues in 2011, azole-resistant Aspergillus DNA was found in 55.1% of 
culture-negative BAL-samples.[26,27] Such an approach could also be used for 
surveillance and allow more exact estimates of azole resistance than through 
culture surveillance only. However, the detection of a low load of Aspergillus 
DNA in plasma and serum remains problematic, and more sensitive non-culture 
based assays for these specimen still have to be developed. 
Although our surveillance studies have shown that the incidence of 
azole-resistance among A. fumigatus vary considerably between institutes, 
recent studies have shown that even within a single institute, incidences may 
vary between departments. In one study, an incidence of 26% was found in 
culture-positive ICU-patients, which was much higher than the incidence in 
other hospital departments (14%; p=0.06). An explanation for the intra-hospital 
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differences of incidences may be found in the fact that treatment of patients with 
azole-resistant disease fails necessitating transferal to the ICU due progressive 
fungal disease.[28] In another study the primary A. fumigatus cultures were 
investigated from hematology and ICU-patients. A higher incidence of azole-
resistance was found in hematology patients compared with ICU (26% versus 
4.5%, respectively).[29] These observations are of importance for clinical decision 
making regarding the choice of primary therapy in patients suspected of invasive 
aspergillosis. An international expert panel recently recommended to consider 
avoiding azole monotherapy as initial antifungal therapy when the incidence of 
azole-resistance exceeded 10%.[30] This would indicate that detailed audits are 
required to establish the local resistance frequencies in different patient groups. 
‘Environmental’ resistance mechanisms were found to be the dominant 
cause of azole-resistant Aspergillus disease in our surveillance studies. The 
clinical implications of this route of resistance are considerable as we were 
unable to identify risk factors for azole-resistant Aspergillus disease. Between 
64% and 71% of patients had no history of previous azole therapy. Furthermore, 
unlike resistance mediated through patient therapy, any Aspergillus disease in 
any patient could be caused by environmental resistance mutations. Clinical 
microbiology laboratories need to perform in vitro susceptibility testing of 
clinical A. fumigatus isolates to determine their local azole-resistance incidence. 
In addition, A. fumigatus isolates recovered from clinical samples need to be 
subjected to susceptibility testing if antifungal treatment is required. If MIC-
testing of Aspergilli is not available locally, isolates should be sent to a mycology 
reference laboratory. However, diagnosing azole-resistant Aspergillus disease 
is difficult even in culture-positive patients, as cultures may harbor azole-
susceptible and azole-resistant colonies concomitantly.[31] It will be difficult for 
clinical microbiology laboratories to determine which colonies are to be selected 
for in vitro susceptibility testing. The approach of sub-culturing A. fumigatus 
colonies on agar supplemented with azoles, which was used in our surveillance 
studies is attractive for patient management as well.[32] Colonies that grow on 
the azole-supplemented agar have a high probability of resistance and these 
could be selected for MIC-testing or sent to a mycology reference laboratory. 
Initiatives to commercialize the agar-based screening agar (VIPcheckTM) are taken 
in order to make this approach available to clinical microbiology laboratories. 
Growth on azole-containing agar may prompt the treating physician to move 
away from azole monotherapy, while awaiting MIC results, as the likelihood of 
resistance in those isolates is very high.
 Since 1998 three resistance mechanisms have been found in both 
environment and patients in the Netherlands: TR34/L98H since 1998; TR53 since 
2006 and TR46/Y121F/T289A since 2009. The emergence of new mutations over 
time indicates that the current use of azole fungicides is not durable, and new 
mutations will continue to emerge. Indeed very recently a fourth resistance 
mechanism (TR92/Y121F/M172V/T289A/G448S) was found in the environment 
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and in clinical isolates (P.E. Verweij, unpublished data). As in medicine we are 
confronted with the consequences of azole resistance, every effort should be 
made to prevent new mutations emerging in the environment. Azole fungicides 
have an important role in food production and prevention of spoilage, and 
therefore any measures should be aimed at retaining the use of azoles both in 
medicine and for food production. Effective measures can only been designed 
if resistance selection in the environment is understood. Research should 
be aimed at understanding how and when azole resistance mutations arise 
in A. fumigatus in order to determine which interventions will prevent this 
occurring. Some investigators argue that the application of azoles is important 
for resistance selection, rather than the volume that is used.[33,34] Exposure to 
high concentrations may comprise the greatest risk, although this is debated by 
others.[35] Nevertheless sites which are considered at high risk for resistance 
should be investigated as a first step to unravel resistance selection. Such research 
requires international and multidisciplinary collaboration, bringing together 
researchers from different fields including mycology, genetics, epidemiology, 
medicine and agriculture. However, the urgency of the resistance problem 
needs to be recognized by governments and scientific communities. Although a 
sense of urgency regarding bacterial resistance is apparent at this level, funds to 
investigate fungal resistance should also be made available. Moreover, it is likely 
that both fields may benefit from each other when addressing the emerging 
threats in parallel.
In the meantime, the number of patients and physicians confronted 
with azole resistance will continue to increase. The high mortality rates that 
we have observed in our surveillance studies have been confirmed by others.
[36,37] The presence of azole resistance probably at least doubles the mortality 
rate in patients with invasive aspergillosis. As we have included only culture-
positive patients in our studies, it is likely that their disease is more progressed 
(compared with culture-negative patients) and therefore mortality rates should 
be compared with those of patients with culture-positive azole-susceptible 
invasive aspergillosis. To obtain a more accurate estimate of the attributable 
mortality of azole resistant invasive aspergillosis patients should be matched 
with controls with disease caused by azole-susceptible isolates. Given the fact 
that azole resistant invasive aspergillosis is still uncommon, a prospective 
multicenter registry enrolling patients with azole-resistant and –susceptible 
invasive aspergillosis would be an appropriate study design.
The current treatment guidelines do not incorporate azole resistance, 
although an ESCMID-guideline on the management of diseases caused by 
azole-resistant A. fumigatus is due shortly. An expert panel recently discussed 
the management of azole resistance providing care-pathways to aid physicians 
to make clinical decisions.[30] In the absence of conclusive clinical studies, the 
experts relied on their own experience and preclinical studies. Most experts 
favored liposomal amphotericin B for the treatment of patients with documented 
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azole-resistant Aspergillus diseases. However, opinions differed when addressing 
at which threshold azole monotherapy should be avoided. Most experts 
recommended a threshold of azole prevalence of 10% and alternative primary 
treatment options included voriconazole in combination with an echinocandin 
or liposomal amphotericin B. Some experts regarded liposomal amphotericin B 
less effective than voriconazole, but a head-to-head comparison of the two drugs 
has never been performed. Clearly more research is needed to determine the 
best approach in regions with high resistance rates. Other combinations, such as 
liposomal amphotericin B in combination with voriconazole, may be attractive 
as empirical therapy but requires further studies. However, some manifestations 
of azole-resistant Aspergillus disease have no alternative treatment option with 
comparable efficacy to a mould-active azole. The most pressing example is 
CNS aspergillosis that is virtually untreatable when the use of voriconazole is 
precluded. The mortality rate of azole-resistant CNS aspergillosis will approach 
that of the pre-azole era, e.g. 95% to 99%.[38] New antifungal drug targets are 
needed to improve the prognosis of these patients although this will take many 
years before such drugs are clinically available. Therefore the efficacy of ‘old’ 
drugs, such as flucytosine and rifampicine, or alternative administration routes, 
i.e. directly into the CSF will need to be explored.
113
6
References
1. Snelders E, van der Lee H, Kuijpers J, et al. Emergence of azole resistance in 
Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 
2008;5:e219.
2. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in 
Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364-8.
3. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus 
resistance mechanism conferring in vitro cross-resistance to azole antifungals 
involves a combination of cyp51A alterations. Antimicrob Agents Chemother 
2007;51:1897-904.
4. Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other 
molds in respiratory samples from patients with cystic fibrosis: a laboratory-
based study with focus on Aspergillus fumigatus azole resistance. J Clin 
Microbiol 2011;49:2243-51. 
5. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. 
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global 
surveillance study is primarily due to the TR/L98H mutation in the cyp51A 
gene. Antimicrob Agents Chemother 2011;55:4465-8.  
6. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying 
the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 
2012;67:362-6.  
7. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, 
Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and 
other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 
2010;54:4545-9. 
8. Lagrou K, De Vleeschouwer J, Meerseman W, et al. Triazole resistance 
among 229 clinical Aspergillus fumigatus isolates. In: 3rd Advances Against 
Aspergillosis 2008; Miami 230, USA: Abstract 33. 
9. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant 
Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. 
Antimicrob Agents Chemother 2012;56:869-74.  
10. Morio F, Aubin GG, Danner-Boucher I, et al. High prevalence of triazole 
resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in 
a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 
2012;67:1870-3.
11. Alanio A, Sitterlé E, Liance M, et al. Low prevalence of resistance to azoles in 
Aspergillus fumigatus in a French cohort of patients treated for haematological 
malignancies. J Antimicrob Chemother 2011;66:371-4.  
12. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus 
species to itraconazole and amphotericin B acquired resistance to 
itraconazole. Scand J Infect Dis 1997;29:509-12.
13. Seyedmousavi S, Hashemi SJ, Zibafar E, et al. Azole-Resistant Aspergillus 
114   |   General discussion and prospects for the future. 
fumigatus, Iran. Emerg Infect Dis 2013;19:832-4. 
14. Astvad KM, Jensen RH, Hassan TM, et al. First detection of TR46/Y121F/T289A 
and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive 
patients in Denmark despite negative findings in the environment. Antimicrob 
Agents Chemother 2014;58:5096-101. 
15. Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant Aspergillus 
fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. 
Euro Surveill 2012;17:pii 20326. 
16. Vermeulen E, De Bel A, Nulens E, et al. Epidemiology of Aspergillus resistance 
in Belgium: results of the Belgian Mycoses Surveillance Network. In: 23rd 
European Conference on Clinical Microbiology and Infectious Diseases 2013; 
Berlin, Germany: abstract O468.
17. Steinmann J, Hamprecht A, Vehreschild MJ, et al. Emergence of azole-resistant 
invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 
2015;70:1522-6.
18. Vazquez JA, Manavathu EK. Molecular Characterization of a Voriconazole-
resistant, Posaconazole-susceptible, Aspergillus fumigatus Isolate in a Lung 
Transplant Recipient in the United States. Antimicrob Agents Chemother 
2015;60:1129-33.
19. Wiederhold NP, Garcia Gil V, Gutierrez F, et al. First Detection of TR34/L98H and 
TR46/Y121F/T289A Cyp51 Mutations in Aspergillus fumigatus isolates in the 
United States. J Clin Microbiol 2016;54:168-71.
20. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, et al. Prevalence and 
molecular characterization of azole resistance in Aspergillus spp. isolates from 
German cystic fibrosis patients. J Antimicrob Chemother 2014;69:1533-6.
21. Lavergne RA, Morio F, Favennec L, et al. First description of azole-resistant 
Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. 
Antimicrob Agents Chemother 2015;59:4331-5.
22. Pelaez T, Monteiro MC, Garcia-Rubio R, Bouza E, Gomez-Lopez A, Mellado E. 
First detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A 
TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes New Infect 
2015;6:33-4.
23. Chen Y, Wang H, Lu Z, et al. Emergence of TR46/Y121F/T289A in an Aspergillus 
fumigatus Isolate from a Chinese Patient. Antimicrob Agents Chemother 
2015;59:7148-50. 
24. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij 
PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue 
specimens. J Clin Microbiol 2010;48:1478-80. 
25. Chong GL, van de Sande WW, Dingemans GJ, et al. Validation of a new 
Aspergillus real-time PCR assay for direct detection of Aspergillus and azole 
resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin 
Microbiol 2015;53:868-74. 
26. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance 
115
6
found in nonculturable Aspergillus fumigatus from lungs of patients with 
chronic fungal disease. Clin Infect Dis 2011;52:1123-9. 
27. Spiess B, Postina P, Reinwald M, et al. Incidence of Cyp51 A key 
mutations in Aspergillus fumigatus-a study on primary clinical samples 
of immunocompromised patients in the period of 1995-2013. PLoS One 
2014;9:e103113. 
28. Russcher A, van Paassen J, Dofferhoff PA, Kuijper EJ. High azole resistance rate 
of Aspergillus fumigatus at Intensive Care Unit in a dutch tertiary hospital. Ned 
Tijdschr Med Microbiol 2014;22:S121. 
29. Fuhren J, Voskuil WS, Boel CHE, Haas PJA, Meis JF, Kusters JG. High prevalence 
of azole resistance in Aspergillus fumigatus isolates from high risk patients. J 
Antimicrob Chemother 2015;70:2894-8.
30. Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on 
the management of infection caused by azole-resistant Aspergillus fumigatus. 
Drug Resist Updat 2015;21-22:30-40.
31. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of 
itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in 
routine cultures. J Antimicrob Chemother 2015;70:412-5.
32. van der Linden JWM, Arendrup MC, van der Lee HAL, Melchers WJG, Verweij 
PE. Azole containing agar plates as a screening tool for azole resistance of 
Aspergillus fumigatus. Mycoses 2009;52:S1-19.
33. Gisi U. Assessment of selection and resistance risk for demethylation inhibitor 
fungicides in Aspergillus fumigatus in agriculture and medicine: a critical 
review. Pest Manag Sci 2014;70:352-64. 
34. Stensvold CR, Jorgensen LN, Arendrup MC. Azole-resistant invasive 
aspergillosis: relationship to agriculture. Curr Fungal Infect Rep 2012;6:178-91.
35. van den Bosch F, Paveley N, Shaw M, Hobbelen P, Oliver R. The dose rate 
debate: does the risk of fungicide resistance increase or decrease with dose? 
Plant Pathology 2011;60:597-606.
36. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole 
resistance in Aspergillus fumigatus associated with treatment failure. Emerg 
Infect Dis 2009;15:1068-76.
37. Seyedmousavi S, Mouton JW, Melchers WJ, Brüggemann RJ, Verweij PE. The 
role of azoles in the management of azole-resistant aspergillosis: from the 
bench to the bedside. Drug Resist Updat 2014;17:37-50. 
38. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 
1996;23:608-15.         
 
 
 
 
 
 

117
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix: 
 Summary and main conclusions  
 Samenvatting en conclusies       
 Dankwoord
    Curriculum Vitae 
    List of publications          
    Oral presentations at (inter)national    
  conferences and symposia

Summary and main conclusions          |   119
A
Summary and main conclusions  
Aspergillus is a saprophytic mould, which is, due to its sporulating capacity, 
spread worldwide through the environment. As a consequence of new tools of 
species identification, i.e. multilocus sequence-based phylogenetic analyses, 
numerous Aspergillus species have been identified to be able to cause a wide 
variety of diseases. In this thesis, we focused on disease caused by Aspergillus 
fumigatus (A. fumigatus) being the main cause of acute (angio-)invasive and 
chronic pulmonary aspergillosis. For adequate treatment of patients with 
aspergillosis, besides a prompt diagnosis, prompt initiation and targeted 
antifungal treatment is of utmost importance. Currently there are 3 classes of 
antifungal drugs with activity to A. fumigatus, being the polyenes, azoles and 
echinocandins. Besides the fact that the recent taxonomic changes have led 
to the classification of cryptic species of A. fumigatus being intrinsically less 
susceptible to the azole-class of antifungals, acquired azole-resistance in A. 
fumigatus sensu stricto is emerging.  
The studies as presented in this this thesis were performed to obtain a better 
insight in the frequency of azole resistance through surveillance of clinical 
A. fumigatus isolates. In addition to the investigation and description of the 
epidemiology of azole resistance, its distribution and trends in resistance 
mechanisms, we also aimed to identify risk factors associated with azole-
resistant Aspergillus disease.
Chapter 2 describes the characteristics of azole resistance selection through 
patient therapy. Nine consecutive isogenic A. fumigatus isolates cultured from 
a patient with pulmonary aspergilloma and azole therapy were investigated 
for azole resistance. The ﬁrst cultured isolate showed a wild-type phenotype, 
but four azole-resistant phenotypes were observed in the subsequent eight 
isolates. Using a Cyp51A homology model and recombination experiments, in 
which mutations were introduced into a susceptible isolate, two substitutions 
at codons P216 and F219 were shown to be both associated with resistance to 
itraconazole and posaconazole for the first time, besides a mutation at codon 
G54, which previously showed to be associated with resistance. We performed a 
review of the literature and showed that in patients who develop azole resistance 
during therapy, multiple resistance mechanisms commonly emerge. The patients 
were probably initially colonized or infected with a susceptible isolate, and over 
time, through azole exposure, resistance developed in this initial isolate. In our 
review all patients were diagnosed with aspergilloma and chronic pulmonary 
aspergillosis. It was previously suggested that in the case of aspergilloma or 
cavitary aspergillus disease, the fungus is able to undergo multiple generations in 
the patient by the asexual way of reproduction. Sporulation (as can be observed 
in cavitary Aspergillus lung disease) as opposed to invasive hyphal growth may 
be important to facilitate the expression of the azole-resistant phenotypes. The 
median time between the last cultured wild-type isolate and the ﬁrst azole-
120   |   Summary and main conclusions
resistant isolate was 4 months (range 3 weeks to 23 months), indicating a rapid 
induction of resistance.
In Chapter 3, the results of a prospective nationwide multicenter surveillance 
study to obtain insight in the extensiveness and consequences azole resistance 
on patient management strategies and public health, is presented. All Aspergillus 
isolates cultured from clinical samples from 7 university medical microbiology 
laboratories in the Netherlands were routinely subcultured on Sabouraud agar 
slants supplemented with 4 mg/L of itraconazole. Isolates able to grow on thos 
slants were sent in to our laboratory for genotypic and susceptibility analyses. 
Clinical data was obtained as well. In total 2,062 isolates from 1,385 patients 
were screened and the prevalence of itraconazole resistance in A. fumigatus 
was 5.3%. Patients with a hematologic or oncologic disorder were more likely to 
harbor an azole-resistant isolate than were other patient groups (p<0.05). Most 
patients (64%) from whom a resistant isolate was identiﬁed were azole naïve 
and the majority (90%) harbored the same resistance mechanism (TR34/L98H), 
indicating an environmental route of resistance development. The case-fatality 
rate of patients with azole-resistant invasive aspergillosis (8 patients) was 
88%. In summary, the results of this nationwide study showed that multi-azole 
resistance in A. fumigatus is widespread in the Netherlands with a very high 
mortality rate among patients with invasive aspergillosis caused by an azole-
resistant A. fumigatus isolate. 
Chapter 4 underscores the necessity of continuation of surveillance for 
detection of azole-resistance, as a new resistance-mechanism was detected 
after continuation of the previously described surveillance in the Netherlands. A 
new cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) was observed 
in 21 azole-resistant A. fumigatus isolates from 15 patients in 6 hospitals by using 
a further developed screening method, using 4-well Sabouraud agar plates 
supplemented with three azoles (itraconazole, voriconazole and posaconazole). 
TR46/Y121F/T289A isolates were highly resistant to voriconazole. Eight patients 
presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment 
failed in all 5 patients receiving primary therapy with voriconazole. Thereby, 
TR46/Y121F/T289A A. fumigatus is severely compromising our first-line treatment 
of invasive aspergillosis with voriconazole. In order to examine the prevalence of 
this new resistance mechanism in A. fumigatus we performed an environmental 
screening by obtaining air samples from several Dutch geographically 
unrelated areas. TR46/Y121F/T289A A. fumigatus was recovered from 6 of the 10 
environmental sites and were genetically related to clinical resistant isolates, 
emphasing the environmental route of resistance development.
As azole resistance in A. fumigatus was emerging in the Netherlands, there was 
a growing need for examination of the global burden of this problem. Therefore 
we set up an international screening program for detection of azole resistance 
worldwide. In Chapter 5, the results of an international screening program 
performed within the context of a prospective multicenter international 
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surveillance study are presented. A total of 3,788 Aspergillus isolates were 
screened in 22 centers from 19 countries, by using the Dutch 4-well plates. Azole-
resistant A. fumigatus was more frequently and more widespread found than 
previously acknowledged, and was detected in 11 of 17 participating European 
centers in 9 countries. An overall prevalence of azole resistance worldwide was 
calculated at 3.2%. A majority of isolates from patients with acute invasive 
aspergillosis harbored the TR34/L98H mutation, but was not observed in patients 
with aspergilloma and chronic pulmonary aspergillosis. Azole-resistant invasive 
aspergillosis was documented in 5.1% of patients of invasive aspergillosis and 
was associated with a dismal outcome. To conclude, azole-resistant A. fumigatus 
is not restricted to the Netherlands, but is encountered on a global scale. The 
management of disease caused by azole-resistant A. fumigatus should be 
reconsidered within the lights of these results.
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Samenvatting en conclusies
Aspergillus is een saprofytaire schimmel, welke zich door zijn sporenvormende 
eigenschappen wereldwijd door de omgeving heeft verspreid. Ten gevolge van 
nieuwe methoden om species te identificeren, zoals multilocus sequence-based 
fylogenitische analyses, zijn inmiddels een groot aantal Aspergillus species 
geïdentificeerd als veroorzakers van een breed scala aan ziektebeelden. In dit 
proefschrift werd voornamelijk gericht op Aspergillus fumigatus (A. fumigatus), 
welke acute (angio-)invasieve en chronische pulmonale aspergillose kan 
veroorzaken. Voor een adequate behandeling van patiënten met aspergillose 
zijn, behoudens een zo vroeg mogelijke diagnose en tijdige start van behandeling 
ook de doelgerichtheid ervan cruciaal. Op dit moment zijn 3 drie verschillende 
klassen antifungale middelen beschikbaar die gebruikt kunnen worden tegen 
A. fumigatus, zijnde polyenen, azolen en echinocandines. Naast het feit dat 
alle recent taxonomische ontwikkelingen hebben geleid tot de ontdekking 
van cryptic species die intrinsiek resistent zijn voor azolen, is ook verworven 
resistentie bij A. fumigatus sensu stricto een opkomend probleem. 
De onderzoeken beschreven in dit proefschrift zijn verricht om meer inzicht 
te verkrijgen in het vóórkomen van azool-resistentie bij klinische A. fumigatus 
isolaten doormiddel van surveillance programma’s. Naast de beschrijving van de 
epidemiologie van azool-resistentie, door onderzoek naar de verspreiding ervan 
en trends in resistentie mechanismen, hebben we gemeend om risicofactoren 
voor het verkrijgen van azool-resistente Aspergillus ziekte te identificeren.
In Hoofdstuk 2 wordt ingegaan op de karakteristieken van het verkrijgen van 
azool-resistentie ten gevolge van de behandeling van patiënten met azolen. 
Negen isogenetische A. fumigatus isolaten werden achtereenvolgens gekweekt 
uit een patiënt met een pulmonaal aspergilloom en azool-behandeling. Alle 
isolaten werden onderzocht op de aanwezigheid van azool-resistentie. Het 
eerste isolaat was een wild-type isolaat, maar 4 verschillende resistente 
fenotypen werden ontdekt in de 8 daaropvolgende isolaten. Met behulp van 
een Cyp51A homologie-model en recombinant analyses werden 2 mutaties 
(substituties in codon P216 en F219) ingebracht in een wild-type azool-gevoelig 
isolaat, waarbij beide mutaties geassocieerd konden worden met resistentie 
voor itraconazol en posaconazol. Tevens werd een mutatie gevonden in codon 
G54, welke al eerder werd gerelateerd aan azool-resistentie. Daarnaast hebben 
we een literatuuronderzoek verricht, waarbij we lieten zien dat in patiënten 
die behandeld worden met azolen vaak een diversiteit aan mutaties wordt 
gevonden. Waarschijnlijk zijn deze patiënten initieel gekoloniseerd of primair 
geïnfecteerd met een gevoelig isolaat, welke door blootstelling aan azolen 
in de loop van de tijd resistentie heeft ontwikkeld. In dit gepresenteerde 
literatuuroverzicht leden ook alle patiënten aan chronische pulmonale 
aspergillose of hadden een aspergilloom, hetgeen overeenkomt met eerdere 
reports waarin wordt gesuggereerd dat in het geval van een aspergilloom of bij 
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holtevormende aspergillusziekte, de schimmel in de mogelijkheid wordt gesteld 
om zich middels asexuele reproductie te kunnen voortplanten en zo meerdere 
generaties te kunnen voortbrengen. Sporulatie, in plaats van doorgroei van 
hyfen, bij deze specifieke ziektebeelden zou kunnen zorgen voor expressie van 
de verschillende resistente fenotypen. Overigens is de mediane tijd tussen de 
laatst gekweekte wild-type isolaat en eerste resistente isolaat gemiddeld 4 
maanden (met een range van 3 weken tot 23 maanden), wat een snelle inductie 
van resistentie betekent. 
In Hoofdstuk 3 wordt een prospectieve, nationale, multicenter surveillance 
beschreven, welke werd opgezet om meer inzicht te verkrijgen in de 
uitgebreidheid en gevolgen van azool-resistentie voor patiënt-management 
strategieën en public health. Hiervoor werden alle gekweekte Aspergillus 
isolaten uit klinische materialen van 7 Nederlandse universitaire medisch-
microbiologische laboratoria routinematig overgekweekt in reageerbuizen met 
een Sabouraud agar-medium waaraan 4 mg/L itraconazol was toegevoegd. Alle 
isolaten welke groeiden in deze buizen werden ingestuurd naar ons laboratorium 
van het Radboud UMC Nijmegen, tezamen met klinische data van de patiënt, 
ten behoeve van statistische, genotypische en gevoeligheidsanalyses. In totaal 
werden 2.062 isolaten van 1.385 patiënten gescreend op resistentie voor 
itraconazol, en werd een prevalentiecijfer berekend van 5,3% (range 0,8%-
9,5%) onder patiënten, waarbij patiënten met hematologisch of oncologisch 
onderliggend lijden eerder een azool-resistent isolaat leken te verkrijgen dan 
patiënten met een ander onderliggend lijden (p<0,05). De meeste patiënten 
(64%) waaruit een resistent isolaat werd gekweekt waren nooit voorbehandeld 
met azolen en en de meerderheid (90%) van de isolaten vertoonden hetzelfde 
resistentie mechanisme (TR34L98H), hetgeen aangeeft dat blootstelling van A. 
fumigatus aan azolen in de omgeving een andere plausibele oorzaak is voor 
ontwikkeling van resistentie. De mortaliteit onder patienten met azool-resistente 
invasieve aspergillose (8 patiënten) bedroeg 88%. Samengevat, toonde deze 
nationale studie aan dat multiazool-resistentie bij A. fumigatus wijdverspreid 
voorkomt in Nederland en dat het is geassocieerd met een hoge mortaliteit 
onder patienten met invasieve azool-resistente aspergillose.
Hoofdstuk 4 ondersteunt het belang van voortgaande surveillance voor de 
detectie van azool-resistente isolaten, daar een nieuw resistentie-mechanisme 
werd ontdekt na continuering van de eerder beschreven surveillance in Nederland. 
Een nieuw cyp51A-gemedieerd resistentie-mechanisme (TR46/Y121F/T289A) 
werd gezien bij 21 azool-resistente isolaten van 15 verschillende patiënten uit 6 
ziekenhuizen, middels een verder ontwikkelde screeningsmethode met 4-wells 
Sabouraud agar platen welke 3 verschillende azolen bevatten (itraconazol, 
voriconazol en posaconazol). TR46/Y121F/T289A isolaten bleken resistant 
voor voriconazol. Acht patiënten leden aan invasieve aspergillose met TR46/
Y121F/T289A, en de behandeling faalde bij alle 5 de patiënten die voriconazol 
ontvingen als eerste-keus therapie. Daarom zorgt TR46/Y121F/T289A A. fumigatus 
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voor een ernstige tekortkoming van onze eerste-keus behandeling van invasieve 
aspergillose met voriconazol. Daarnaast werden luchtmonsters genomen op 
diverse geografisch-ongerelateerde regio’s in Nederland, om de prevalentie van 
deze nieuwe mutatie in A. fumigatus in de omgeving te onderzoeken. Resistente 
TR46/Y121F/T289A A. fumigatus werd ontdekt bij 6 van de 10 bemonsterde regio’s 
en bleek genetisch gerelateerd aan resistente isolaten gekweekt uit patiënten, 
wat de hypothese van de ontwikkeling van resistentie in de omgeving verder 
onderstreept. 
Met de opkomst van azool-resistentie onder A. fumigatus in Nederland was 
er noodzaak om het vóórkomen van dit probleem op wereldwijde schaal te 
gaan onderzoeken. Om deze reden hebben wij een internationaal screenings-
programma opgezet om de prevalentie van azool-resistentie wereldwijd te 
kunnen beschrijven. In Hoofdstuk 5 worden de resultaten van een prospectieve, 
multicenter, internationale surveillance gepresenteerd. In totaal werden 3.788 
Aspergillus isolaten uit 22 centra uit 19 landen gescreend met behulp van de 
Nederlandse 4-wells azoolplaten. Azool-resistente A. fumigatus bleek vaker en 
meer wijdverspreid voor te komen dan eerder bevestigd, en werd gedetecteerd 
bij 11 van de 17 deelnemende Europese centra uit 9 verschillende landen. Het 
prevalentiecijfer van azool-resistentie wereldwijd werd berekend op 3,2%. Het 
merendeel van de isolaten met de TR34/L98H mutatie werd gedetecteerd bij 
patiënten met acute invasieve aspergillose, in vergelijking met de patiënten 
met aspergillomen en chronische pulmonale aspergillusziekte, waar dat 
niet werd gezien. Azool-resistentie kwam voor bij 5,1% van de patiënten met 
invasieve aspergillose en werd geassocieerd met een verslechterde outcome. 
Concluderend is het vóórkomen van azool-resistentie bij A. fumigatus dus 
niet beperkt gebleven tot Nederland en komt op wereldwijde schaal voor. 
Het handelen rondom ziekte veroorzaakt door azool-resistente A. fumigatus 
moet derhalve worden heroverwogen met bovengenoemde resultaten in het 
achterhoofd. 
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Dankwoord
Enige jaren geleden had ik niet gedacht te zijn aanbeland waar ik nu ben. 
Waar ik als nuchtere generalist nooit had verwacht deze wetenschappelijke 
tocht te maken is nu dan toch de eindbestemming bereikt. Dit onderzoek 
heeft me de afgelopen jaren gevormd tot de clinicus die ik nu ben. Ik 
startte met een lege rugzak, maar heb deze de afgelopen jaren mogen 
vullen met op de bodem de wetenschappelijke basis, later opgevuld met 
wetenschappelijke verdieping en nu bovenop een afgerond proefschrift als 
kroon op het werk. Dit was me in mijn eentje nooit gelukt, onderweg zijn er 
vele gidsen en reismaatjes meer of minder betrokken geweest. Samen hebben 
we het eindpunt bereikt en daar ben ik veel mensen erg dankbaar voor. 
Prof. dr. Paul Verweij, promotor. Beste Paul, dank voor alle steun en vertrouwen 
bij het tot stand komen van dit proefschrift. Na elk overleg ging ik weer 
boordevol verse inspiratie aan de slag met het volgende onderzoek. Het samen 
brainstormen over ontstaanswijzen van resistentie en alles tot op de bodem 
uitzoeken heeft mij gevormd tot de onderzoekende clinicus die ik nu ben. Blijven 
graven en zoeken tot je het antwoord hebt heb ik van jou mogen leren. Veel dank 
daarvoor! 
Daarnaast heb je jouw ongrijpbare enthousiasme voor de wonderlijke wereld van 
de microbiologie aan mij over weten te dragen. Ooit heb je me verteld waarom die 
wereld zo bijzonder is, ‘de wereld van de microbiologie is altijd in ontwikkeling, 
staat nooit stil en je kunt nooit voorspellen hoe de micro-organismen zich van 
de ene op de andere dag kunnen evolueren’, en dat heb ik aan den lijve mogen 
ondervinden: ook ik ben verliefd geworden op de wonderlijke wereld van de 
medische microbiologie… je staat er telkens weer van versteld.
Prof. dr. Adilia Warris, promotor. Beste Adilia, waar ik op precies 10 januari 2008 
bij je aanklopte met de vraag of je misschien wat leuks had liggen voor een 
onderzoeksstage in het kader van mijn studie geneeskunde, staan we nu waar we 
staan: met dit proefschrift in handen! In eerste instantie had ik helemaal geen zin in 
een wetenschappelijke stage, maar toen ik mocht ervaren welke zelfontplooiing 
en verdieping wetenschappelijk onderzoek met zich mee bracht was ik om. 
Ondanks het feit dat ik je door de start van mijn opleiding tot kinderarts en jouw 
vertrek naar Schotland maar kort in de kliniek heb kunnen ervaren, ben ik je 
toch zeer erkentelijk voor jouw begeleiding met toch altijd weer een persoonlijke 
noot. Ik denk graag terug aan de cursussen pediatrische mycologie die we bij 
verschillende universiteiten in Nederland samen hebben mogen verzorgen (en 
de reis daar naartoe!), de begeleiding van de studenten geneeskunde en de late 
uurtjes waarin we telefonisch nog ‘even’ bespraken wat er allemaal uit de stapels 
dossiers van de patiënten met invasieve schimmelinfecties naar voren kwam. Het 
is vooral jouw voorliefde voor de kliniek die er voor gezorgd heeft dat er naast het 
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fundamentele onderzoek ook oog is geweest voor klinische kant van patiënten 
met (schimmel)infecties. Daar bloeit mijn klinische hart nog elke dag van op. 
 
Dr. Willem Melchers, co-promotor. Beste Willem, heel graag wil ik je danken 
voor je enthousiasme, humor en diepgewortelde kennis van de moleculaire 
microbiologie die je aan mij hebt overgedragen. Met veel plezier denk ik terug aan 
die keer dat we samen naar het Pantheon op het Atheense Akropolis stonden te 
staren, terwijl we eigenlijk nog een horde aan posterpresentaties op het congres 
hadden moeten aanschouwen, toch denk ik dat dit ook heel erg leuk was… 
Members of the Doctoral Thesis Committee, Prof. dr. D.M. Burger, Prof. dr. 
M.G. Netea en Prof. dr. A.H. Groll (Westfälische Wilhelms-Universität Münster, 
Germany), I would like to thank you for reading and judgement of this thesis. 
Fantastisch team van mycologie van MMB Nijmegen, of wat zeg ik: het beste 
mycologisch team aan mycologisch analisten van Nederland! Ton Rijs, Hein van 
der Lee, Diane Lamers-Jansen en Jan Zoll enorm bedankt voor alle leerzame 
momenten en praktische begeleiding op het lab. Ik heb met veel plezier drie jaar 
lang met jullie opgetrokken in het lab. De koffiepauzes buiten staat me nog goed 
bij! En bij deze nogmaals de belofte: de barbecue komt eraan!
Graag wil ik ook bedanken alle student die op grote of kleine wijze betrokken zijn 
geweest bij de uitvoering van de diverse onderzoeken. Van data vergaring tot 
lab-ondersteuning, veel hulp heb ik van jullie gehad. Dankjewel Lonneke Aarts, 
Jantine Knoop en Marijke Koens.
Beste mede- en oud-promovendi van MMB, in het bijzonder Eveline Snelders, 
Roger Brüggemann, Dewi van der Vegt, Amir Seyedmousavi en Simone Camps. 
Een aantal jaren hebben we naast het lab zelf onze eigen promovendus-
kamer gehad. Daar waar nodig hebben we elkaar ondersteund in praktische 
werkzaamheden, maar waren we met elkaar soms ook een fantastische 
denktank! Dankjulliewel!
Daarnaast ben ik veel dank verschuldigd aan alle onderzoekers en clinici die bij dit 
onderzoek betrokken zijn geweest, dit zijn er werkelijk te veel om op te noemen. 
Alle onderzoekers uit de academische centra betrokken bij de Nederlandse 
surveillance, van de lab-analisten die resistente stammen naar ons lab hebben 
ingestuurd tot de arts-microbiologen die online alle data hebben ingevoerd. 
Hetzelfde geldt voor alle onderzoekers uit de ruim 20 internationale centra die 
betrokken waren bij het SCARE-onderzoek. I would like to thank all members 
of our SCARE-network for their participation and willingness to provide their 
data. Without your support our understanding of the development and spread 
of resistance would not be that great. Thank you very much.
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Tevens heb ik veel respect voor alle patiënten met schimmelinfecties die 
betrokken zijn geweest bij de diverse onderzoeken. Alle patiënten die 
vragenlijsten hebben ingevuld en alle mensen die bereid waren om hun 
huis open te stellen voor de luchtbemonstering. Heel veel dank voor jullie 
medewerking en betrokkenheid.       
Uiteraard moet ik ook al mijn collegae kindergeneeskunde bedanken. Alle AIOS 
kindergeneeskunde in Arnhem en Nijmegen, bedankt dat jullie jezelf elke keer 
weer lieten onderdompelen in de wondere wereld van de schimmels op elk 
onderwijsmoment die er maar te vinden was. Promoveren is leuk, maar om al voor 
je promotie door je directe collega’s benoemd te worden als ‘Jan de Schimmelman’ 
is een heel mooi compliment. Daarnaast verdienen alle kinderartsen uit 
de vakgroepen algemene kindergeneeskunde, kinderinfectiezieken/-
immunologie en kinderoncologie een woord van dank, voor alle gelegenheid 
die zij mij geboden hebben om mijn expertise op dit gebied verder te vergroten. 
Tevens een speciaal woord van dank aan opleiders Jos Draaisma en Anneke 
Landsta. Zij hebben mij de ruimte gegeven om ook tijdens mijn opleiding tot 
kinderarts dit proefschrift af te maken en tussendoor ook nog te genieten 
van de wetenschappelijke verdieping die dit met zich heeft meegebracht.  
 
Maatjes van CV Roar mar Woar, medeleiding van Scouting Schaijk en bestuursleden 
Jeugdcarnaval Schaijk en Carnaval de Moeslanden. Soms kwamen jullie op de 
tweede plaats. Toch verdient jullie geduld een groot woord van dank, op alle 
momenten dat ik weer eens te laat was of jullie moest vragen om bepaalde taken 
van mij over te nemen. 
Teun, Kevin, Mark, Hans, Niels, Frank, Johan, Sander, Luuk, Martijn, Ton, Jaap, 
Maurice, Harald, Harm, Corné, Daniel, Peter, Roel, Mark, Mandy, Masja, Linda, 
Maartje, Monica, Sanne, Dianne, Kristel, Kim, Ilona, Auke, Elissa, Pleun en Saskia, 
eigenlijk hoef ik er niet veel woorden aan vuil te maken: gezelligheid voorop! We 
vatten d’r nog wel eentje op! 
Een speciaal woord van dank aan mijn paranimfen, Elke en Harm. Het is voor 
mij een eer dat jullie mijn paranimfen willen zijn. Elke, altijd boordevol energie, 
rechtdoorzee en als het niet linksom kan dan maar rechtsom. Soms zou ik wat 
meer van jou in mijzelf willen hebben, dan was dit proefschrift misschien al vier 
jaar geleden afgerond… En jij Harm, Herrum lange derrum, vele mooie momenten 
met elkaar meegemaakt, onder andere aan een stiek in Nepal en in een tuinhuisje 
in Venetië. Jij weet van niets toch weer altijd iets te maken. Bedankt dat jij ook 
hieraan je steentje wilt bijdragen!
En dan, de allermeeste dank ben ik toch wel verschuldigd aan jullie, pap en mam. 
Ondanks het feit dat jullie niet altijd snapten waar ik altijd maar mee bezig was 
daar in Nijmegen heb ik toch altijd jullie trots mogen ervaren. Elk steuntje in de 
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rug heb ik aan jullie te danken, voor alles kan ik altijd bij jullie terecht. Heel heel 
heel veel dank voor alle ruimte die jullie mij gegeven hebben om te worden tot 
wie ik ben. Samen met Gijs en Aniek is het echt altijd een warm thuis bij jullie 
en hebben jullie ons alles gegeven wat een kind nodig heeft. Dankjulliewel. 
 
Maar ook jij, lieve Paul. Het afgelopen jaar heeft veel in het teken gestaan 
van de afronding van dit proefschrift en samen zijn we blij dat het dan toch 
eindelijk is afgerond. Nu eindelijk samen tijd voor andere dingen en wordt jouw 
geduld hopelijk wat minder op de proef gesteld. Ik bewonder jouw flexibiliteit 
en mag mezelf gelukkig prijzen dat jij degene bent die in dit proces naast mij 
heeft gestaan. Een maatje om op te bouwen. We gaan samen een fantastische 
toekomst tegemoet met meer tijd voor elkaar, dankjewel!
Hoewel dit het eindpunt is van deze route, sta ik nog op een kruispunt vanwaar 
zich vele wegen afsplitsen. Er zijn nog talloze mogelijkheden, van verdere 
wetenschappelijke activiteiten met nieuwe onderzoeken tot verdere verdieping 
in de kliniek. Hopelijk zijn er een aantal parallelwegen te bewandelen en kunnen 
er nog vele routes worden afgelegd.
Jan van der Linden 
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Jan Wilhelmus Marinus van der Linden werd geboren in Nijmegen op 7 februari 
1984 en groeide op in het Brabantse Schaijk. Na het behalen van zijn tweetalig-
VWO diploma aan het Maaslandcollege in Oss ging Jan in 2002 geneeskunde 
studeren aan de Radboud Universiteit te Nijmegen. Gedurende zijn studie 
heeft Jan reeds profilering gezocht binnen de kindergeneeskunde door middel 
van keuzevakken als acute levensbedreigende aandoeningen bij kinderen, 
genetische en metabole ziekten en de impact van chronische aandoeningen bij 
het kind. Na een senior co-schap algemene kindergeneeskunde heeft Jan aan het 
einde van zijn geneeskunde studie gedurende 3 maanden een wetenschappelijke 
onderzoeksstage verricht op de afdelingen Medische Microbiologie en 
Kindergeneeskunde van het Radboud UMC te Nijmegen. Dit betrof een onderzoek 
naar het voorkomen van azool-resistentie onder Aspergillus niger, onder leiding 
van Prof. Dr. A. Warris (voorheen kinderarts-infectioloog/immunoloog Radboud 
UMC te Nijmegen). Na afloop van deze wetenschappelijke stage behaalde Jan 
in augustus 2008 zijn artsdiploma en begon hij aan een ZonMW-gesubsidieerd 
promotietraject naar de epidemiologie van azool resistentie bij patienten met 
invasieve aspergillose, onder begeleiding van Prof. Dr. P.E. Verweij, Prof. Dr. A 
Warris en Dr. W.J.G. Melchers, wat geresulteerd heeft in de totstandkoming 
van dit proefschrift. Tijdens zijn wetenschappelijke werkzaamheden heeft Jan 
diverse congressen en symposia bijgewoond en uitkomsten van zijn studies 
gepresenteerd in Washington, Brussel, Nice, Chicago, Athene, Rome en Madrid.
Gedurende de beginjaren van zijn promotietraject was Jan tot mei 2011 
werkzaam als ANIOS (arts niet in opleiding tot specialist) op de afdeling 
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